research
education
treatment
prevention
early detection

Saskatchewan Cancer Agency

Excellence in Patient Care & Cancer Control

ANNUAL REPORT 2000-2001

Table of Contents

102-01528/

Letter of Transmittal	2
Mission, Vision, Values and Organization	3
Report of the Board Chairperson	4
Report of the Chief Executive Officer	6
Organizational Chart	9
Agency Mandate Area Highlights	
• Treatment	10
• Prevention and Early Detection	12
• Research	13
• Education	13
Statistical Tables	14
Public Information	26
Report of Management	27
Financial Statements	28
Research Projects	40
Publications	44
Abstracts and Proceedings	46
Sylvia Fedoruk Prize in Medical Physics	48

Letter of Transmittal

The Honourable John T. Nilson, Q.C.
Minister of Health
Province of Saskatchewan
Legislative Building
Regina, Saskatchewan
S4S 0B3

Dear Mr. Nilson:

As the Chairperson of the Saskatchewan Cancer Agency Board of Directors, I have the honour to submit herewith the report of the activities of the Saskatchewan Cancer Agency for the fiscal year ending March 31, 2001.

Respectfully submitted,

(Ms.) Pat Krueger
Chairperson

Mission ...

"Excellence in patient care and cancer control"

Vision ...

"An improved quality of life and health of people by minimizing the impact of cancer"

Values ...

Respect
Equity
Excellence
Accountability
Compassion
Honesty

Board of Directors

Ms. Pat Krueger, North Battleford (Chairperson)
Ms. Kathy Zaitsoff, Saskatoon (Vice-Chairperson)
Dr. Borden Bachynski, Regina (until June 2000)
Ms. Lena Dubray, Meadow Lake
Ms. Diana Ermel, Regina (August 2000)
Ms. Mary Gilliland, Saskatoon (August 2000)
Ms. Marion Heavin, Melfort
Dr. Craig Milne, Regina
Ms. Jean Perkins, Codette
Dr. David Popkin, Saskatoon
Mr. Gary Semenchuck, Regina
Ms. Dolores Tumbach, Leader (August 2000)

Management Coordinating Committee

Mr. Bob Allen	Chief Executive Officer
Mr. Dennis Karakochuk	Executive Director Human Resources
Ms. Nancy Guebert	Executive Director Education and Corporate Affairs
Dr. Arthur Firth (until September 2001)	Executive Director Allan Blair Cancer Centre
Dr. Tan Suan Goh (October 2001)	Acting Executive Director Allan Blair Cancer Centre
Ms. Huguette Gauthier	Associate Executive Director Allan Blair Cancer Centre
Dr. Mohamed Mohamed	Executive Director Saskatoon Cancer Centre
Mr. Ivan Olfert	Associate Executive Director Saskatoon Cancer Centre
Dr. Svein Carlsen	Executive Director Health Research
Mr. Bill Morton	Executive Director Information Management
Mr. Kevin Lacey	Executive Director Finance
Ms. Lois Harrison	Director Screening Programs

Report of the Chairperson

The Saskatchewan Cancer Agency is guided by the mandate set out in the *Cancer Foundation Act* and is committed to provision of quality patient care and cancer control for the Province of Saskatchewan. An ever-increasing number of new patients and subsequent pressures on treatment services, a situation projected to be the norm for the next several years, challenges the Agency's ability to provide education, research, prevention and early detection essential to making a difference in future cancer statistics.

The Agency is appreciative of support from the Government of Saskatchewan in providing funding for a number of capital equipment projects. The Saskatoon Cancer Centre marked completion of the first of these projects with the opening of a new Varian Linear Accelerator and state-of-the-art treatment planning system in October 2000. This equipment is used to deliver radiation treatment to cancer patients. A similar project is underway at the Allan Blair Cancer Centre with completion targeted for the fall of 2002.

Board Policy Development

The Board and senior management came together for a retreat in October 2000. Its focus was the following:

- Cancer Past, Present and Future: a review and analysis of trends, projections and expected impacts of the disease of cancer in Saskatchewan.
- Alternative Revenue Generation: study of options for generating supplemental revenues.
- Governance Information Needs.
- Submission to the Fyke Commission.

Linkages

The Board's commitment and responsibility to the community is set out in a stakeholder and community linkage policy. As a direct result of this policy, community forums, which provided an opportunity for the Agency to link directly with the public were held in Meadow Lake, Prince Albert and Weyburn during the past year. We extend thanks to staff, local organizations and individuals who contributed to the success of these events.

Monitoring

Health agencies frequently ask themselves, "How well are we doing in delivery of health services?" The decision to participate in accreditation under the Canadian Council of Health Services Accreditation with the new AIM standards was, in fact, a cross-Agency commitment to quality improvement. The Accreditation Report with recommendations has become the umbrella for a process to monitor progress and set priorities toward achieving the Agency's goals. Key components of the plan are:

- Accreditation Response to High Urgency and Medium Urgency Recommendations: The Accreditation Report prioritizes recommendations and sets timelines for response and report.
- A Quality Management Plan: Teams within the Agency have selected performance indicators which, by regular monitoring, measure progress toward quality improvement.
- A Strategic Plan: An action plan has been developed to address Agency goals under research, education, treatment, prevention and early detection. Phase-in is set to occur over a three-year period with a targeted completion of April 2003.

Report of the Chairperson

Medical Appointments

The Board commends its management for successful recruitment of a number of new physicians to the Agency's medical staff. This is not insignificant, considering the shortage of oncologists in Canada. On the recommendation of management, the Board approved medical appointments, including:

- Allan Blair Cancer Centre - Dr. Osama Koriech, Director of Radiation Oncology and Dr. Mohammad Haq, Pediatric Oncologist.
- Saskatoon Cancer Centre - Dr. Amer Sami and Dr. Kamal Haider, Medical Oncologists, Dr. Christopher Mpofu, Pediatric Oncologist and Dr. Ali El-Gayed, Radiation Oncologist.

It was with regret that the Agency received the announcement of the retirement of Dr. Arthur Firth, Executive Director of the Allan Blair Cancer Centre. Dr. Firth pioneered the first in Canada and only one (to date) HDR Brachytherapy treatment for prostate cancer. We wish him well in his retirement on the Isle of Whight. Dr. T.S. Goh assumed responsibilities as Acting Executive Director.

Board Membership

Consistent with the Agency's mandate, the Board of Directors is comprised of members that come from diverse backgrounds and geographic locations across the province. In August, we welcomed three new members to the Board - Mary Gilliland of Saskatoon, Diana Ermel of Regina and Dolores Tumbach of Leader - and are appreciative of the addition of their unique perspectives, expertise and experience, which serve to strengthen the Board in its deliberations.

A Very Special Event

When Lisa Rendall, popular morning show co-host at Saskatoon's C95 radio station, was diagnosed with breast cancer in the summer 2000, she decided to dedicate her personal battle with the disease into a public opportunity to raise funds to support breast cancer research in Saskatchewan. As a result, proceeds of Saskatoon's C95 Radio Marathon were dedicated to breast cancer research being conducted at the Saskatoon Cancer Centre. The collaborative efforts of Lisa, C95 morning host "Rambling" Dave Sharf, co-host Rob Suski and crew, breast cancer survivors and staff of the Saskatchewan Cancer Agency raised a total of $124,000, not to mention awareness of prevention and early detection of breast cancer. Words are totally inadequate to express appreciation to those who participated.

In conclusion, I wish to extend sincere appreciation to all members of the Board, management and staff of the Saskatchewan Cancer Agency for their dedication and commitment to our Mission, Vision, Values and Goals.

Respectfully submitted,

Pat Krueger
Chairperson

Report of the Chief Executive Officer

It is my pleasure to provide the following summary of the Saskatchewan Cancer Agency's activities for the 2000 - 2001 fiscal year.

Last year I reported on a new reorganization of the Agency to mirror its mandated responsibilities of providing cancer research, education, treatment, prevention and early detection. As can be seen on the front cover of this report, we also updated our Agency visual identity to better illustrate these changes.

The Saskatchewan Cancer Agency faces increasing demand for cancer services as well as expectations from the public. The population demographics for Saskatchewan and Canada point to an ageing population, resulting in significant increases in cancer incidence in future years.

The Agency has identified the following strategic initiatives as a way to assist in achieving Agency goals and objectives in order to prepare to meet the increase in demands and expectations:

- Developing best practice and clinical guidelines for cancer treatment on a provincial basis.
- Continuing recruitment and retention initiatives to ensure adequate supply of health professionals available to provide timely services.
- Developing a plan to obtain long-term funding of capital equipment.
- Developing and expanding quality improvement and monitoring programs.
- Developing opportunities for reducing the scope and cost of cancer treatments through prevention and early detection.
- Developing and implementing a comprehensive integrated Information Management system.

Strategic Initiatives

Best Practice and Clinical Guidelines

The Agency is working to develop provincial standards, including the utilization of clinical practice guidelines for cancer treatment. As a provincial body, we also take responsibility for monitoring and measuring the effectiveness of programs to ensure we are meeting the stated standards. We are also working with other provincial cancer agencies to develop quality standards at the national level.

Recruitment and Retention Initiatives

The Agency continues to use some of the more traditional methods of recruitment including journal advertising, participation at job fairs and overseas recruitment drives. We have also taken specific initiatives to make working in Saskatchewan more attractive. For example, oncologists from other countries look to Saskatchewan as a preferred place to work because of special provisioning for licensure allowed by the College of Physicians and Surgeons of Saskatchewan.

Report of the Chief Executive Officer

Long-term Funding of Capital Equipment

The Agency has established a capital equipment plan for the replacement of ageing treatment equipment, much of which is 15 years and older. This $20 million, three-year plan will see the replacement of older equipment, thus ensuring Saskatchewan residents have access to the latest in diagnostic and treatment equipment and facilities. Our ability to attract and retain health professionals is also greatly influenced by their access to state-of-the-art equipment.

We are grateful to the Government of Saskatchewan for providing the Agency with over $6 million in funding for capital replacement, new equipment, and capital construction over the past year. A continuance of this commitment by government is essential in order for the Agency to complete this capital equipment renewal program.

Quality Improvement and Monitoring Programs

In August, the Agency established, as part of its quality improvement program, the use of quality indicator tools to monitor quality within the organization. Each Department identified two indicators to track over the coming year. The outcome of this quality monitoring will be reported to the Board on a semi-annual basis. For this year, a total of 58 quality indicators have been identified and monitored. The program will be expanded to include a greater variety of indicators in the coming years.

The results of this new program will help in measuring program effectiveness and identify necessary changes required to further improve cancer services.

Scope and Cost of Cancer Treatments Through Prevention and Early Detection

The Agency is taking a leading role in placing greater emphasis on prevention and early detection services through its Education Services Division's public forums, other education programs, and through the Screening Program for Breast Cancer. The health system of the future needs to put far greater emphasis on targeting illnesses and diseases that are clearly preventable. Cancer is the leading cause of premature death. Factors such as smoking, diet and environmental influences all contribute to the development of this disease.

Screening initiatives such as the Screening Program for Breast Cancer, established ten years ago in Saskatchewan, have had a positive effect on breast cancer in women in the province. Data indicates an increase in the number of cancers detected at earlier stages (Stage 1 & 2) and a decrease in the number of late-staged cancers detected (Stage 3 & 4).

Integrated Information Management System

An Information Management Strategy for the Agency has been developed and initial steps to implement the strategy are in progress. Implementation of the strategy, over approximately a four year period, will be one of the most significant steps in ensuring the long-term future and success of the Agency in providing timely and state-of-the-art cancer services for Saskatchewan residents.

Modern information systems will enable us to maximize our future opportunities. They will enable us to make properly informed evidence-based decisions, measure our outcomes more effectively and ensure quality services are maintained and enhanced. Implementation of the strategy will also enable us to keep pace with other provincial cancer agencies in the effective use of Information Technology.

Report of the Chief Executive Officer

Collaborative Relationships

By the nature of our work, it is imperative that the Agency develops strong collaborative relationships with other health providers in the current system. These collaborative partnerships are essential to the success of the Agency delivering its programs and services. Some of the key partners of the Agency are Saskatchewan Health, the health districts, the University of Saskatchewan - College of Medicine, and the Canadian Cancer Society - Saskatchewan Division.

The Agency also has partnerships on a national basis with our involvement on the Canadian Association of Provincial Cancer Agencies (CAPCA). CAPCA is developing a number of strategic initiatives that will bring significant benefits to the province. These include:

- Development of a national human resource planning model for cancer professionals.
- Development of national cancer standards.
- Creation of a technology assessment process.
- Development of standard information services.
- Processes for continued communication and education on cancer issues nationally.

In addition, the Agency, as a part of CAPCA, is fully committed to the implementation of the Canadian Strategy for Cancer Control, jointly developed by CAPCA, the Canadian Cancer Society, and the National Cancer Institute of Canada.

In Conclusion

I would like to take this opportunity to thank the staff and volunteers at the Agency for their continued hard work and dedication to our mission of providing excellence in patient care and cancer control for the people of Saskatchewan. I also thank our many partners and other health sector organizations that have contributed to our success over the past year.

Bob Allen
Chief Executive Officer

Organizational Chart



Treatment

Allan Blair and Saskatoon Cancer Centres



The Saskatoon Cancer Centre welcomed new state-of-the-art radiation therapy equipment last October.

In October 2000, the Saskatoon Cancer Centre hosted a grand opening for a new Varian dual energy linear accelerator radidation therapy machine and a new three-dimensional treatment planning system. The new linear accelerator has the ability to send a radiation beam in the exact shape of a particular tumor, which will ensure that only the target areas receive treatment. Prior to this technology, beams were sent in a squared pattern and required a radiation therapist to slide shielding blocks to change the shape of the radiation beam going into the patient. A three-dimensional treatment planning system will customize a treatment plan based on an individual's particular tumor size, shape and density. The information gathered will form the actual treatment to be given by the linear accelerator.

During 2000 - 2001, $3 million provided by Saskatchewan Health was used to purchase a Linear Accelerator, CT Simulator and three-dimensional treatment planning system for the Allan Blair Cancer Centre. An additional $1.235 million was provided for related building construction and renovations to house this new equipement. Construction began in spring 2001.

Saskatchewan Health also provided the Agency with $1.85 million to purchase various pieces of radiation equipment for both Cancer Centres.

Lymphoedema Program

In January 2000, the Lymphoedema Program commenced at the Allan Blair Cancer Centre in partnership with the Regina Health District. There are two components to this program:

- An education program for women who have undergone axillary surgery and are about to receive radiotherapy or chemotherapy. This education component has now been in progress for a year.

- A treatment program for women who have developed the condition. During this past year, over 100 post-surgical clients, plus some family members and staff, have received information on the prevention of post-surgical complications, such as lymphoedema, infection, cording and radiation capsulitis.

Assessment and treatment numbers in the Lymphoedema Program have continued to grow with over 150 new patients seen in 2000, compared to 60 patients in 1999.

Agency Mandate Area Highlights

Provincial Stem Cell Transplant Program

The Provincial Stem Cell Transplant Program, situated at the Saskatoon Cancer Centre, continued to expand to include allogenic transplants (transplants from an outside/external donor). There were 12 patients treated with non-myeloablative allogenic transplants. Prior to inception of the Stem Cell Program, patients requiring allogenic transplants were referred out of province. There were 15 autologous transplants also performed during the year.

The Stem Cell Transplant Program became a member of the International Bone Marrow Transplant Registry.

The Community Oncology Program of Saskatchewan (COPS)

This program is co-ordinated by the Saskatoon Cancer Centre (SCC) and the Allan Blair Cancer Centre (ABCC) in partnership with the health districts. This program allows selective chemotherapy treatments to be administered in certified centres throughout the province enabling patients to receive treatment within their own community.

Currently, there are 22 certified COPS centres in the province. In addition, there are communities/institutions throughout the province that administer a limited group of treatments, providing they are in compliance with Occupational Health and Safety and Saskatchewan Cancer Agency policies, standards, and guidelines for the safe preparation, administration, handling and disposal of cancer chemotherapy.

The COPS program is in the process of conducting a province-wide formal evaluation that will indicate what services are presently available in each community, and assist in determining minimal criteria for a community to be designated a COPS centre.

Clinical, educational, operational and administrative support is provided to COPS Centres by the COPS Co-ordinators, located at the SCC and ABCC. This support comes in the form of site visits, Reaching Out newsletter, in-services, formal education programs, and day to day contact with the community via phone, fax and e-mail.

Pat Yuzik, COPS Co-ordinator at SCC and Cheryl Whiting, COPS Co-ordinator at ABCC manage the provincial COPS program.

A formal partnership agreement, request for treatment, statistical database, and a website to support COPS is currently being developed. The Agency is also building national linkages with health care professionals involved in community cancer care across the country.

Supportive Care

Social workers in the Agency, located at the Allan Blair Cancer Cenre and Saskatoon Cancer Centre, work in tandem with a patient's treatment program to provide a variety of services, including assessment and consultation, personal services and counselling. Social workers at the two Centres see about 200 new patients each per year. On average, each social worker also sees 65 patients per month.

Social workers at both Centres are also involved with various support groups, such as Look Good Feel Better, Prostate Cancer and Relaxation offering guidance and counsel. They also remain committed to providing academic lectures and workshops to educational institutions and community organizations and groups. The Agency also provided practicum supervision for two graduate study Psychology students in 2000-2001.

Volunteers at the Agency

There are 90 volunteers at both the Allan Blair Cancer Centre and the Saskatoon Cancer Centre. Volunteers are an integral part of the daily operations of the Agency. They escort patients to their treatments or diagnostic tests and help patients select wigs and turbans, among other services. There were over 8,000 volunteer hours put in last year at both of the Centres. Approximately 31,350 kilometres were driven by volunteers at the Allan Blair Cancer Centre last year to bring patients to their appointments.

Cancer Patient Lodges

Cancer Patients Lodges located in Regina and Saskatoon provide room and board for out-of-town patients with cancer. They continue to be viewed as a "home away from home" for these patients. The total number of occupied patient beds for the year was 8,713.

Radiologists screen films to detect cancer at an early stage.

Prevention and Early Detection

Screening Program for Breast Cancer

In the area of screening and prevention, the Agency is responsible for the provincial Screening Program for Breast Cancer with seven stationary sites around the province, as well as a mobile mammography unit, which travels into communities not served by the stationary centres. The Screening Program has the highest participation rate in Canada with over 35,000 mammograms annually.

Agency Mandate Area Highlights

Research

The Research Division of the Agency is located within the Saskatoon Cancer Centre, providing research in the areas of basic science and translational research. Epidemiology and clinical trials research take place at both the Saskatoon Cancer Centre and the Allan Blair Cancer Centre.

Basic science attempts to determine the underlying differences between normal and cancerous cells. Translational research takes the results of basic research and applies them in a clinical environment (from the lab to the bedside). Epidemiology is the study of health and disease in populations and application of this study to control health problems. Clinical trials are the scientific method of studying a new cancer treatment designed for specific types of cancer within a clinical setting.

In October 2000, a successful radio-marathon for breast cancer was held with Saskatoon radio station, C95. The proceeds from this marathon went directly to breast cancer research being conducted within the Health Research Division of the Agency.

Please see pages 40 to 43 for a complete listing of research projects.

Research is conducted in the areas of basic science, translational, epidemiology and clinical trials at the Saskatchewan Cancer Agency.

Education

The Education Services Division of the Agency began holding public forums in conjunction with the health districts. The content included an overview of the Saskatchewan Cancer Agency, hereditary cancers, early detection and prevention, what happens if you get cancer, and "a survivor's story". Total attendance was 101. These were held in Meadow Lake, Weyburn and Prince Albert.

Presentations throughout the province included such topics as the Screening Program for Breast Cancer, lifestyle and risk reduction, information on screenable cancers. Audiences included high school students, First Nation's people, government and private sector staff, university students and the general public.

ALLAN BLAIR CANCER CENTRE STATISTICS 1996 - 2000

Clinic Appointments

	1996	1997	1998	1999	2000
New Patient Appointments	1,913	1,913	1,918	2,058	2,185
Review Patient Appointments	12,175	11,799	12,594	12,359	14,044
Radiotherapy Treatments	15,587	15,488	16,700	17,596	18,118
Chemotherapy	4,275	4,655	5,463	5,745	7,578

Radiotherapy Treatment Visits by Machine Type

	1996	1997	1998	1999	2000
Brachytherapy	83	92	79	143	162
Linear Accelerator	12,401	12,703	13,676	14,868	15,466
Cobalt	2,589	2,223	2,697	2,414	2,373
Stabilipan	514	470	248	171	117
TOTALS	15,587	15,488	16,700	17,596	18,118

Health Record Activities

	1996	1997	1998	1999	2000
Case Registrations	3,596	3,790	4,161	4,427	4,500
Case Visits Recorded	14,503	14,220	15,290	14,512	16,162
Follow-up Reports	13,099	12,473	11,816	12,262	11,805

Statistical Tables

SASKATOON CANCER CENTRE STATISTICS 1996 - 2000

Clinic Appointments

	1996	1997	1998	1999	2000
New Patient Appointments	1,793	2,077	2,197	2,042	2,012
Review Patient Appointments	14,329	13,356	13,598	13,376	13,552
Radiotherapy Treatments	17,210	18,522	18,854	17,487	16,075
Chemotherapy	5,571	5,234	5,708	4,896	4,627

Radiotherapy Treatment Visits by Machine Type

	1996	1997	1998	1999	2000
Brachytherapy	12	17	21	8	15
Linear Accelerator	17,146	18,126	18,326	17,041	15,594
X-ray	278	379	507	446	481
TOTALS	17436	18,522	18,854	17,495	16,090

Health Record Activities

	1996	1997	1998	1999	2000
Case Registrations	3,761	3,779	3,962	4,134	3,974
Case Visits Recorded	14,108	13,859	13,675	13,032	12,810
Follow-up Reports	12,011	11,778	11,627	12,169	12,336

ALLAN BLAIR CANCER CENTRE STATISTICS 1996 - 2000

Clinic Appointments

	1996	1997	1998	1999	2000
New Patient Appointments	1,913	1,913	1,918	2,058	2,185
Review Patient Appointments	12,175	11,799	12,594	12,359	14,044
Radiotherapy Treatments	15,587	15,488	16,700	17,596	18,118
Chemotherapy	4,275	4,855	5,463	5,745	7,578

Radiotherapy Treatment Visits by Machine Type

	1996	1997	1998	1999	2000
Brachytherapy	83	92	79	143	162
Linear Accelerator	12,401	12,703	13,676	14,868	15,466
Cobalt	2,589	2,223	2,697	2,414	2,373
Stabilipan	514	470	248	171	117
TOTALS	15,587	15,488	16,700	17,596	18,118

Health Record Activities

	1996	1997	1998	1999	2000
Case Registrations	3,596	3,790	4,161	4,427	4,500
Case Visits Recorded	14,503	14,220	15,290	14,512	16,162
Follow-up Reports	13,099	12,473	11,816	12,262	11,805

Statistical Tables

SASKATOON CANCER CENTRE STATISTICS 1996 - 2000

Clinic Appointments

	1996	1997	1998	1999	2000
New Patient Appointments	1,793	2,077	2,197	2,042	2,012
Review Patient Appointments	14,329	13,356	13,598	13,376	13,552
Radiotherapy Treatments	17,210	18,522	18,854	17,487	16,075
Chemotherapy	5,571	5,234	5,708	4,896	4,627

Radiotherapy Treatment Visits by Machine Type

	1996	1997	1998	1999	2000
Brachytherapy	12	17	21	8	15
Linear Accelerator	17,146	18,126	18,326	17,041	15,594
X-ray	278	379	507	446	481
TOTALS	17436	18,522	18,854	17,495	16,090

Health Record Activities

	1996	1997	1998	1999	2000
Case Registrations	3,761	3,779	3,962	4,134	3,974
Case Visits Recorded	14,108	13,859	13,675	13,032	12,810
Follow-up Reports	12,011	11,778	11,627	12,169	12,336

SCREENING PROGRAM FOR BREAST CANCER STATISTICS 1996 - 2000

Centre		1996	1997	1998	1999	2000
Regina	# of Mammograms	8,105	8,727	8,148	9,396	9,387
	# of Abnormals	645	640	637	707	699
	# of Cancers	59	51	42	58	44
Saskatoon	# of Mammograms	6,149	6,742	6,686	7,072	7,333
	# of Abnormals	507	651	535	605	662
	# of Cancers	31	43	31	35	37
Swift Current	# of Mammograms	924	1,296	1,189	1,431	1,349
	# of Abnormals	60	88	86	108	92
	# of Cancers	5	11	5	9	4
North Battleford	# of Mammograms	1,111	1,596	1,351	1,530	1,654
	# of Abnormals	100	138	96	132	153
	# of Cancers	10	10	5	7	8
Yorkton	# of Mammograms	2,380	2,480	2,780	2,712	2,767
	# of Abnormals	170	192	194	208	200
	# of Cancers	13	19	6	12	11
Moose Jaw	# of Mammograms	1,641	1,708	1,787	1,593	2,020
	# of Abnormals	108	143	141	141	143
	# of Cancers	8	16	10	6	14
Prince Albert	# of Mammograms	1,737	2,374	2,037	2,255	2,548
	# of Abnormals	127	174	172	196	247
	# of Cancers	7	18	9	8	11
Mobile	# of Mammograms	6,843	9,035	10,115	9,085	8,312
	# of Abnormals	550	643	735	646	602
	# of Cancers	39	65	40	46	36
TOTAL	# of Mammograms	28,890	33,958	34,093	35,074	35,370
	# of Abnormals	2,267	2,669	2,596	2,743	2,798
	# of Cancers	172	233	148	181	165

Statistical Tables

INCIDENCE -- AGE-SPECIFIC NUMBERS (MALE) -- 2000

SITE	AGE GROUPS														
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0	0	0	0	0	1	0	1	0	3	2	4	4	5	10	30
Oral Cavity	0	0	0	0	0	0	1	0	3	1	5	6	1	2	4	23
Head and Neck	0	0	0	0	0	1	1	1	1	2	1	5	3	3	5	23
Esophagus	0	0	0	0	0	0	0	2	1	3	4	5	5	5	5	30
Stomach	0	0	0	0	1	0	2	2	2	7	7	6	5	13	12	57
Colon	0	0	0	0	2	1	7	7	7	17	17	25	31	36	49	199
Rectum	0	0	0	0	2	1	2	5	9	11	21	18	20	19	15	123
Liver	0	0	0	0	0	0	0	2	1	0	1	1	3	2	1	11
Gall Bladder and Biliary Tract	0	0	0	0	0	0	0	0	0	0	3	3	3	3	4	16
Pancreas	0	0	0	0	0	0	2	0	1	4	3	4	5	12	7	38
Digestive Tract	0	0	0	0	0	0	0	0	1	0	1	1	0	0	1	4
Larynx	0	0	0	0	0	0	0	0	1	3	4	5	4	2	4	23
Trachea, Bronchus and Lung	0	0	0	0	0	0	3	6	9	24	42	56	70	63	61	334
Respiratory System	1	0	0	0	0	0	1	0	1	1	3	0	1	1	3	12
Bone and Connective Tissue	1	2	0	1	1	1	2	1	4	1	4	0	1	4	3	26
Malignant Melanoma of Skin	0	0	0	1	2	0	5	7	10	5	5	6	7	9	4	61
Breast	0	0	0	0	0	0	0	0	0	1	1	0	1	2	0	5
Prostate	0	0	0	0	0	1	3	9	19	53	83	119	181	134	144	746
Male Genital Organs	0	0	3	1	4	9	5	3	1	1	2	1	2	0	0	32
Kidney	0	0	0	0	1	0	4	4	6	7	17	8	9	10	10	76
Bladder	0	0	0	0	0	0	1	5	7	6	18	21	29	32	48	167
Other Urinary Tract	0	0	0	0	0	0	0	0	1	0	1	1	4	4	0	11
Brain and Central Nervous System	2	2	0	3	0	0	3	2	3	3	3	5	4	4	3	37
Thyroid	0	0	0	1	1	0	1	0	2	4	4	4	0	1	0	18
Other Endocrine Glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Lymphoma	2	1	0	1	1	1	8	2	6	11	6	9	13	10	7	78
Hodgkin's Disease	0	5	0	2	1	1	0	0	1	0	0	0	1	0	0	11
Multiple Myeloma	0	0	0	0	0	1	1	2	0	1	4	6	7	5	9	36
Leukemia	7	0	0	0	1	1	3	4	4	10	9	11	8	14	18	90
Primary Unknown	0	0	0	0	1	1	1	2	5	2	6	2	5	7	12	44
Other Primaries	1	0	0	0	1	0	2	1	1	3	3	2	2	3	2	21
TOTALS	14	10	3	10	19	20	58	68	107	184	280	334	429	405	441	2382
Non-Melanoma Skin Cancer	0	0	0	2	9	16	44	45	82	93	121	172	230	246	471	1531
Other: In Situ	0	0	0	1	0	0	1	5	7	13	12	26	26	26	53	170
TOTALS	0	0	0	3	9	16	45	50	89	106	133	198	256	272	524	1701

SCREENING PROGRAM FOR BREAST CANCER STATISTICS 1996 - 2000

Centre		1996	1997	1998	1999	2000
Regina	# of Mammograms	8,105	8,727	8,148	9,396	9,387
	# of Abnormals	645	640	637	707	699
	# of Cancers	59	51	42	58	44
Saskatoon	# of Mammograms	6,149	6,742	6,686	7,072	7,333
	# of Abnormals	507	651	535	605	662
	# of Cancers	31	43	31	35	37
Swift Current	# of Mammograms	924	1,296	1,189	1,431	1,349
	# of Abnormals	60	88	86	108	92
	# of Cancers	5	11	5	9	4
North Battleford	# of Mammograms	1,111	1,596	1,351	1,530	1,654
	# of Abnormals	100	138	96	132	153
	# of Cancers	10	10	5	7	8
Yorkton	# of Mammograms	2,380	2,480	2,780	2,712	2,767
	# of Abnormals	170	192	194	208	200
	# of Cancers	13	19	6	12	11
Moose Jaw	# of Mammograms	1,641	1,708	1,787	1,593	2,020
	# of Abnormals	108	143	141	141	143
	# of Cancers	8	16	10	6	14
Prince Albert	# of Mammograms	1,737	2,374	2,037	2,255	2,548
	# of Abnormals	127	174	172	196	247
	# of Cancers	7	18	9	8	11
Mobile	# of Mammograms	6,843	9,035	10,115	9,085	8,312
	# of Abnormals	550	643	735	646	602
	# of Cancers	39	65	40	46	36
TOTAL	# of Mammograms	28,890	33,958	34,093	35,074	35,370
	# of Abnormals	2,267	2,669	2,596	2,743	2,798
	# of Cancers	172	233	148	181	165

Statistical Tables

INCIDENCE -- AGE-SPECIFIC NUMBERS (MALE) -- 2000

SITE	AGE GROUPS														
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0	0	0	0	0	1	0	1	0	3	2	4	4	5	10	30
Oral Cavity	0	0	0	0	0	0	1	0	3	1	5	6	1	2	4	23
Head and Neck	0	0	0	0	0	1	1	1	1	2	1	5	3	3	5	23
Esophagus	0	0	0	0	0	0	0	2	1	3	4	5	5	5	5	30
Stomach	0	0	0	0	1	0	2	2	2	7	7	6	5	13	12	57
Colon	0	0	0	0	2	1	7	7	7	17	17	25	31	36	49	199
Rectum	0	0	0	0	2	1	2	5	9	11	21	18	20	19	15	123
Liver	0	0	0	0	0	0	0	2	1	0	1	1	3	2	1	11
Gall Bladder and Biliary Tract	0	0	0	0	0	0	0	0	0	0	3	3	3	3	4	16
Pancreas	0	0	0	0	0	0	2	0	1	4	3	4	5	12	7	38
Digestive Tract	0	0	0	0	0	0	0	0	1	0	1	1	0	0	1	4
Larynx	0	0	0	0	0	0	0	0	1	3	4	5	4	2	4	23
Trachea, Bronchus and Lung	0	0	0	0	0	0	3	6	9	24	42	56	70	63	61	334
Respiratory System	1	0	0	0	0	0	1	0	1	1	3	0	1	1	3	12
Bone and Connective Tissue	1	2	0	1	1	1	2	1	4	1	4	0	1	4	3	26
Malignant Melanoma of Skin	0	0	0	1	2	0	5	7	10	5	5	6	7	9	4	61
Breast	0	0	0	0	0	0	0	0	0	1	1	0	1	2	0	5
Prostate	0	0	0	0	0	1	3	9	19	53	83	119	181	134	144	746
Male Genital Organs	0	0	3	1	4	9	5	3	1	1	2	1	2	0	0	32
Kidney	0	0	0	0	1	0	4	4	6	7	17	8	9	10	10	76
Bladder	0	0	0	0	0	0	1	5	7	6	18	21	29	32	48	167
Other Urinary Tract	0	0	0	0	0	0	0	0	1	0	1	1	4	4	0	11
Brain and Central Nervous System	2	2	0	3	0	0	3	2	3	3	3	5	4	4	3	37
Thyroid	0	0	0	1	1	0	1	0	2	4	4	4	0	1	0	18
Other Endocrine Glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Lymphoma	2	1	0	1	1	1	8	2	6	11	6	9	13	10	7	78
Hodgkin's Disease	0	5	0	2	1	1	0	0	1	0	0	0	1	0	0	11
Multiple Myeloma	0	0	0	0	0	1	1	2	0	1	4	6	7	5	9	36
Leukemia	7	0	0	0	1	1	3	4	4	10	9	11	8	14	18	90
Primary Unknown	0	0	0	0	1	1	1	2	5	2	6	2	5	7	12	44
Other Primaries	1	0	0	0	1	0	2	1	1	3	3	2	2	3	2	21
TOTALS	14	10	3	10	19	20	58	68	107	184	280	334	429	405	441	2382
Non-Melanoma Skin Cancer	0	0	0	2	9	16	44	45	82	93	121	172	230	246	471	1531
Other: In Situ	0	0	0	1	0	0	1	5	7	13	12	26	26	26	53	170
TOTALS	0	0	0	3	9	16	45	50	89	106	133	198	256	272	524	1701

INCIDENCE -- AGE-SPECIFIC NUMBERS (FEMALE) -- 2000

SITE	AGE GROUPS															
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0	0	0	0	0	0	1	0	1	0	0	1	0	2	3	8
Oral Cavity	0	0	0	0	0	0	0	1	0	0	2	2	2	3	5	15
Head and Neck	0	0	0	0	0	0	1	1	0	0	0	5	0	1	0	8
Esophagus	0	0	0	0	0	0	0	1	0	1	0	3	4	0	1	10
Stomach	0	0	0	0	0	0	0	1	3	1	2	5	9	8	9	38
Colon	0	0	0	0	0	3	2	8	9	9	11	20	40	22	74	198
Rectum	0	0	0	0	0	1	1	7	6	6	4	9	8	7	25	84
Liver	0	0	0	0	0	0	0	1	0	0	1	0	4	[illegible]	1	8
Gall Bladder and Biliary Tract	0	0	0	0	0	0	0	0	0	1	4	2	2	2	9	20
Pancreas	0	0	0	1	0	1	2	2	0	2	5	6	8	4	12	43
Digestive Tract	0	0	0	0	0	0	0	0	1	0	0	2	1	0	0	4
Larynx	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1	8
Trachea, Bronchus and Lung	0	0	0	1	0	0	1	7	16	26	28	46	47	40	36	248
Respiratory System	0	0	0	1	0	0	0	0	0	0	1	1	2	0	1	6
Bone and Connective Tissue	0	1	0	1	0	0	1	0	1	3	0	1	1	1	3	13
Malignant Melanoma of Skin	0	1	2	0	1	5	5	9	4	3	3	8	4	4	9	58
Breast	0	0	1	2	5	23	37	54	65	54	73	53	75	64	97	603
Cervix, Invasive	0	0	0	3	9	8	8	4	2	3	2	0	0	3	1	43
Uterus	0	0	2	0	1	1	4	11	12	14	15	14	15	13	14	116
Ovary	0	1	0	0	7	2	1	5	7	6	4	5	13	7	16	74
Female Genital Organs	0	0	0	1	0	1	2	1	1	2	0	5	1	2	6	22
Kidney	1	0	0	0	2	0	0	4	1	4	5	3	6	9	9	44
Bladder	0	0	0	1	0	0	0	0	4	4	2	4	9	8	13	45
Other Urinary Tract	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Brain and Central Nervous System	2	2	0	0	0	0	1	1	4	3	4	5	2	4	1	29
Thyroid	0	3	2	1	7	5	8	6	5	3	0	2	0	3	1	46
Other Endocrine Glands	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	2
Lymphoma	0	1	1	0	0	1	4	4	8	9	10	16	12	10	21	97
Hodgkin's Disease	1	2	2	2	0	0	1	3	1	0	0	1	1	1	0	15
Multiple Myeloma	0	0	0	0	0	0	0	2	1	0	1	2	4	4	7	21
Leukemia	2	0	1	0	2	2	3	1	2	7	1	6	9	14	13	63
Primary Unknown	0	0	0	0	0	2	2	0	5	7	5	11	7	9	27	75
Other Primaries	2	0	0	0	0	0	0	2	2	2	2	3	2	1	4	20
TOTALS	8	11	11	14	35	56	85	136	161	171	186	242	289	260	420	2089
Non-Melanoma Skin Cancer	0	0	2	6	14	23	37	53	49	53	69	93	119	174	410	1102
Cervix, In Situ	2	23	85	80	64	49	31	11	8	3	3	0	4	0	1	364
Other, In Situ	0	1	1	2	1	5	12	11	25	22	22	19	40	24	52	237
TOTALS	2	24	88	88	79	77	80	75	82	78	94	112	163	198	463	1703

INCIDENCE -- AGE-SPECIFIC RATES per 100,000 (MALE) -- 2000

SITE	AGE GROUPS														
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0.0	0.0	0.0	0.0	0.0	2.5	0.0	2.8	0.0	13.3	10.4	21.7	24.2	37.3	63.2	5.9
Oral Cavity	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	10.2	4.4	26.0	32.5	6.0	14.9	25.3	4.5
Head and Neck	0.0	0.0	0.0	0.0	0.0	2.5	2.5	2.8	3.4	8.8	5.2	27.1	18.1	22.4	31.6	4.5
Esophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	3.4	13.3	20.8	27.1	30.2	37.3	31.6	5.9
Stomach	0.0	0.0	0.0	0.0	3.1	0.0	5.0	5.5	6.8	31.0	36.4	32.5	30.2	96.9	75.9	11.2
Colon	0.0	0.0	0.0	0.0	6.3	2.5	17.4	19.4	23.8	75.2	88.4	135.6	187.3	268.3	309.9	39.2
Rectum	0.0	0.0	0.0	0.0	6.3	2.5	5.0	13.8	30.6	48.7	109.2	97.6	120.8	141.6	94.9	24.3
Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	3.4	0.0	5.2	5.4	18.1	14.9	6.3	2.2
Gall Bladder and Biliary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.6	16.3	18.1	22.4	25.3	3.2
Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	3.4	17.7	15.6	21.7	30.2	89.4	44.3	7.5
Digestive Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	5.2	5.4	0.0	0.0	6.3	0.8
Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	13.3	20.8	27.1	24.2	14.9	25.3	4.5
Trachea, Bronchus and Lung	0.0	0.0	0.0	0.0	0.0	0.0	7.4	16.6	30.6	106.2	218.5	303.8	422.9	469.6	385.8	65.9
Respiratory System	0.9	0.0	0.0	0.0	0.0	0.0	2.5	0.0	3.4	4.4	15.6	0.0	6.0	7.5	19.0	2.4
Bone and Connective Tissue	0.9	4.8	0.0	3.0	3.1	2.5	5.0	2.8	13.6	4.4	20.8	0.0	6.0	29.8	19.0	5.1
Malignant Melanoma of Skin	0.0	0.0	0.0	3.0	6.3	0.0	12.4	19.4	34.0	22.1	26.0	32.5	42.3	67.1	25.3	12.0
Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	5.2	0.0	6.0	14.9	0.0	1.0
Prostate	0.0	0.0	0.0	0.0	0.0	2.5	7.4	24.9	64.5	234.4	431.7	645.5	1093.6	998.7	910.6	147.1
Male Genital Organs	0.0	0.0	7.9	3.0	12.5	22.9	12.4	8.3	3.4	4.4	10.4	5.4	12.1	0.0	0.0	6.3
Kidney	0.0	0.0	0.0	0.0	3.1	0.0	9.9	11.1	20.4	31.0	88.4	43.4	54.4	74.5	63.2	15.0
Bladder	0.0	0.0	0.0	0.0	0.0	0.0	2.5	13.8	23.8	26.5	93.6	113.9	175.2	238.5	303.6	32.9
Other Urinary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	5.2	5.4	24.2	29.8	0.0	2.2
Brain and Central Nervous System	1.8	4.8	0.0	9.1	0.0	0.0	7.4	5.5	10.2	13.3	15.6	27.1	24.2	29.8	19.0	7.3
Thyroid	0.0	0.0	0.0	3.0	3.1	0.0	2.5	0.0	6.8	17.7	20.8	21.7	0.0	7.5	0.0	3.5
Other Endocrine Glands	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Lymphoma	1.8	2.4	0.0	3.0	3.1	2.5	19.8	5.5	20.4	48.7	31.2	48.8	78.5	74.5	44.3	15.4
Hodgkin's Disease	0.0	12.0	0.0	6.1	3.1	2.5	0.0	0.0	3.4	0.0	0.0	0.0	6.0	0.0	0.0	2.2
Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	2.5	2.5	5.5	0.0	4.4	20.8	32.5	42.3	37.3	56.9	7.1
Leukemia	6.3	0.0	0.0	0.0	3.1	2.5	7.4	11.1	13.6	44.2	46.8	59.7	48.3	104.3	113.8	17.7
Primary Unknown	0.0	0.0	0.0	0.0	3.1	2.5	2.5	5.5	17.0	8.8	31.2	10.8	30.2	52.2	75.9	8.7
Other Primaries	0.9	0.0	0.0	0.0	3.1	0.0	5.0	2.8	3.4	13.3	15.6	10.8	12.1	22.4	12.6	4.1
TOTALS - ALL SITES	469.6															

INCIDENCE – AGE-SPECIFIC NUMBERS (FEMALE) – 2000

SITE	AGE GROUPS															
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0	0	0	0	0	0	1	0	1	0	0	1	0	2	3	8
Oral Cavity	0	0	0	0	0	0	0	1	0	0	2	2	2	3	5	15
Head and Neck	0	0	0	0	0	0	1	1	0	0	0	5	0	1	0	8
Esophagus	0	0	0	0	0	0	0	1	0	1	0	3	4	0	1	10
Stomach	0	0	0	0	0	0	0	1	3	1	2	5	9	8	9	38
Colon	0	0	0	0	0	3	2	8	9	9	11	20	40	22	74	198
Rectum	0	0	0	0	0	1	1	7	6	6	4	9	8	17	25	84
Liver	0	0	0	0	0	0	0	1	0	0	1	0	4	1	1	8
Gall Bladder and Biliary Tract	0	0	0	0	0	0	0	0	0	1	4	2	2	2	9	20
Pancreas	0	0	0	1	0	1	2	2	0	2	5	6	8	4	12	43
Digestive Tract	0	0	0	0	0	0	0	0	1	0	0	2	1	0	0	4
Larynx	0	0	0	0	0	0	0	0	0	1	1	1	1	3	1	8
Trachea, Bronchus and Lung	0	0	0	1	0	0	1	7	16	26	28	46	47	40	36	248
Respiratory System	0	0	0	1	0	0	0	0	0	0	1	1	2	0	1	6
Bone and Connective Tissue	0	1	0	1	0	0	1	0	1	3	0	1	1	1	3	13
Malignant Melanoma of Skin	0	1	2	0	1	5	5	9	4	3	3	8	4	4	9	58
Breast	0	0	1	2	5	23	37	54	65	54	73	53	75	64	97	603
Cervix: Invasive	0	0	0	3	9	8	8	4	2	3	2	0	0	3	1	43
Uterus	0	0	2	0	1	1	4	11	12	14	15	14	15	13	14	116
Ovary	0	1	0	0	7	2	1	5	7	6	4	5	13	7	16	74
Female Genital Organs	0	0	0	1	0	1	2	1	1	2	0	5	1	2	6	22
Kidney	1	0	0	0	2	0	0	4	1	4	5	3	6	9	9	44
Bladder	0	0	0	1	0	0	0	0	4	4	2	4	9	8	13	45
Other Urinary Tract	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Brain and Central Nervous System	2	2	0	0	0	0	1	1	4	3	4	5	2	4	1	29
Thyroid	0	3	2	1	7	5	8	6	5	3	0	2	0	3	1	46
Other Endocrine Glands	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	2
Lymphoma	0	1	1	0	0	1	4	4	8	9	10	16	12	10	21	97
Hodgkin's Disease	1	2	2	2	0	0	1	3	1	0	0	1	1	1	0	15
Multiple Myeloma	0	0	0	0	0	0	0	2	1	0	1	2	4	4	7	21
Leukemia	2	0	1	0	2	2	3	1	2	7	1	6	9	14	13	63
Primary Unknown	0	0	0	0	0	2	2	0	5	7	5	11	7	9	27	75
Other Primaries	2	0	0	0	0	0	0	2	2	2	2	3	2	1	4	20
TOTALS	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Non-Melanoma Skin Cancer	0	0	2	6	14	23	37	53	49	53	69	93	119	174	410	1102
Cervix: In Situ	2	23	85	80	64	49	31	11	8	3	3	0	4	0	1	364
Other: In Situ	0	1	1	2	1	5	12	11	25	22	22	19	40	24	52	237
TOTALS	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●

INCIDENCE -- AGE-SPECIFIC RATES per 100,000 (MALE) -- 2000

SITE	AGE GROUPS														
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0.0	0.0	0.0	0.0	0.0	2.5	0.0	2.8	0.0	13.3	10.4	21.7	24.2	37.3	63.2	
Oral Cavity	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	10.2	4.4	26.0	32.5	6.0	14.9	25.3	
Head and Neck	0.0	0.0	0.0	0.0	0.0	2.5	2.5	2.8	3.4	8.8	5.2	27.1	18.1	22.4	31.6	
Esophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	3.4	13.3	20.8	27.1	30.2	37.3	31.6	
Stomach	0.0	0.0	0.0	0.0	3.1	0.0	5.0	5.5	6.8	31.0	36.4	32.5	30.2	96.9	75.9	
Colon	0.0	0.0	0.0	0.0	6.3	2.5	17.4	19.4	23.8	75.2	88.4	135.6	187.3	268.3	309.9	
Rectum	0.0	0.0	0.0	0.0	6.3	2.5	5.0	13.8	30.6	48.7	109.2	97.6	120.8	141.6	94.9	
Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	3.4	0.0	5.2	5.4	18.1	14.9	6.3	
Gall Bladder and Biliary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.6	16.3	18.1	22.4	25.3	
Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	3.4	17.7	15.6	21.7	30.2	89.4	44.3	
Digestive Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	5.2	5.4	0.0	0.0	6.3	
Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	13.3	20.8	27.1	24.2	14.9	25.3	
Trachea, Bronchus and Lung	0.0	0.0	0.0	0.0	0.0	0.0	7.4	16.6	30.6	106.2	218.5	303.8	422.9	469.6	385.8	
Respiratory System	0.9	0.0	0.0	0.0	0.0	0.0	2.5	0.0	3.4	4.4	15.6	0.0	6.0	7.5	19.0	
Bone and Connective Tissue	0.9	4.8	0.0	3.0	3.1	2.5	5.0	2.8	13.6	4.4	20.8	0.0	6.0	29.8	19.0	
Malignant Melanoma of Skin	0.0	0.0	0.0	3.0	6.3	0.0	12.4	19.4	34.0	22.1	26.0	32.5	42.3	67.1	25.3	
Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	5.2	0.0	6.0	14.9	0.0	
Prostate	0.0	0.0	0.0	0.0	0.0	2.5	7.4	24.9	64.5	234.4	431.7	645.5	1093.6	998.7	910.6	
Male Genital Organs	0.0	0.0	7.9	3.0	12.5	22.9	12.4	8.3	3.4	4.4	10.4	5.4	12.1	0.0	0.0	
Kidney	0.0	0.0	0.0	0.0	3.1	0.0	9.9	11.1	20.4	31.0	88.4	43.4	54.4	74.5	63.2	
Bladder	0.0	0.0	0.0	0.0	0.0	0.0	2.5	13.8	23.8	26.5	93.6	113.9	175.2	238.5	303.6	
Other Urinary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	5.2	5.4	24.2	29.8	0.0	
Brain and Central Nervous System	1.8	4.8	0.0	9.1	0.0	0.0	7.4	5.5	10.2	13.3	15.6	27.1	24.2	29.8	19.0	
Thyroid	0.0	0.0	0.0	3.0	3.1	0.0	2.5	0.0	6.8	17.7	20.8	21.7	0.0	7.5	0.0	
Other Endocrine Glands	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Lymphoma	1.8	2.4	0.0	3.0	3.1	2.5	19.8	5.5	20.4	48.7	31.2	48.8	78.5	74.5	44.3	
Hodgkin's Disease	0.0	12.0	0.0	6.1	3.1	2.5	0.0	0.0	3.4	0.0	0.0	0.0	6.0	0.0	0.0	
Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	2.5	2.5	5.5	0.0	4.4	20.8	32.5	42.3	37.3	56.9	
Leukemia	6.3	0.0	0.0	0.0	3.1	2.5	7.4	11.1	13.6	44.2	46.8	59.7	48.3	104.3	113.8	
Primary Unknown	0.0	0.0	0.0	0.0	3.1	2.5	2.5	5.5	17.0	8.8	31.2	10.8	30.2	52.2	75.9	
Other Primaries	0.9	0.0	0.0	0.0	3.1	0.0	5.0	2.8	3.4	13.3	15.6	10.8	12.1	22.4	12.6	
TOTALS - ALL SITES																

NCIDENCE -- AGE-SPECIFIC RATES per 100,000 (FEMALE) -- 2000

SITE	AGE GROUPS														
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
p	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	3.5	0.0	0.0	5.2	0.0	11.5	10.8	1.6
ral Cavity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	10.1	10.4	10.6	17.3	18.0	2.9
ead and Neck	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.9	0.0	0.0	0.0	25.9	0.0	5.8	0.0	1.6
sophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	4.5	0.0	15.5	21.1	0.0	3.6	1.9
tomach	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	10.4	4.5	10.1	25.9	47.5	46.1	32.3	7.4
olon	0.0	0.0	0.0	0.0	0.0	7.6	5.0	23.0	31.2	40.1	55.5	103.6	211.0	126.7	265.9	38.5
ectum	0.0	0.0	0.0	0.0	0.0	2.5	2.5	20.2	20.8	26.8	20.2	46.6	42.2	97.9	89.8	16.3
ver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	5.0	0.0	21.1	5.8	3.6	1.6
all Bladder and Biliary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	20.2	10.4	10.6	11.5	32.3	3.9
ancreas	0.0	0.0	0.0	3.1	0.0	2.5	5.0	5.8	0.0	8.9	25.2	31.1	42.2	23.0	43.1	8.4
igestive Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	10.4	5.3	0.0	0.0	0.8
arynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	5.0	5.2	5.3	17.3	3.6	1.6
rachea, Bronchus and Lung	0.0	0.0	0.0	3.1	0.0	0.0	2.5	20.2	55.5	115.9	141.4	238.3	248.0	230.3	129.3	48.2
espiratory System	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	5.0	5.2	10.6	0.0	3.6	1.2
one and Connective Tissue	0.0	2.5	0.0	3.1	0.0	0.0	2.5	0.0	3.5	13.4	0.0	5.2	5.3	5.8	10.8	2.5
alignant Melanoma of Skin	0.0	2.5	5.5	0.0	3.1	12.6	12.6	25.9	13.9	13.4	15.1	41.4	21.1	23.0	32.3	11.3
reast	0.0	0.0	2.8	6.3	15.6	58.1	93.1	155.6	225.5	240.8	368.5	274.5	395.7	368.5	348.5	117.2
ervix, Invasive	0.0	0.0	0.0	9.4	28.1	20.2	20.1	11.5	6.9	13.4	10.1	0.0	0.0	17.3	3.6	8.4
terus	0.0	0.0	5.5	0.0	3.1	2.5	10.1	31.7	41.6	62.4	75.7	72.5	79.1	74.8	50.3	22.5
vary	0.0	2.5	0.0	0.0	21.9	5.1	2.5	14.4	24.3	26.8	20.2	25.9	68.6	40.3	57.5	14.4
emale Genital Organs	0.0	0.0	0.0	3.1	0.0	2.5	5.0	2.9	3.5	8.9	0.0	25.9	5.3	11.5	21.6	4.3
dney	0.9	0.0	0.0	0.0	6.2	0.0	0.0	11.5	3.5	17.8	25.2	15.5	31.7	51.8	32.3	8.6
ladder	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	13.9	17.8	10.1	20.7	47.5	46.1	46.7	8.7
ther Urinary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.2
rain and Central Nervous System	1.9	5.1	0.0	0.0	0.0	0.0	2.5	2.9	13.9	13.4	20.2	25.9	10.6	23.0	3.6	5.6
hyroid	0.0	7.6	5.5	3.1	21.9	12.6	20.1	17.3	17.3	13.4	0.0	10.4	0.0	17.3	3.6	8.9
ther Endocrine Glands	0.0	0.0	0.0	0.0	3.1	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4
ymphoma	0.0	2.5	2.8	0.0	0.0	2.5	10.1	11.5	27.8	40.1	50.5	82.9	63.3	57.6	75.4	18.9
odgkin's Disease	0.9	5.1	5.5	6.3	0.0	0.0	2.5	8.6	3.5	0.0	0.0	5.2	5.3	5.8	0.0	2.9
ultiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	3.5	0.0	5.0	10.4	21.1	23.0	25.1	4.1
eukemia	1.9	0.0	2.8	0.0	6.2	5.1	7.6	2.9	6.9	31.2	5.0	31.1	47.5	80.6	46.7	12.2
rimary Unknown	0.0	0.0	0.0	0.0	0.0	5.1	5.0	0.0	17.3	31.2	25.2	57.0	36.9	51.8	97.0	14.6
ther Primaries	1.9	0.0	0.0	0.0	0.0	0.0	0.0	5.8	6.9	8.9	10.1	15.5	10.6	5.8	14.4	3.9
OTALS - ALL SITES	405															

MORTALITY -- AGE-SPECIFIC NUMBERS (MALE) -- 2000

SITE

AGE GROUPS

SITE	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
Oral Cavity	0	0	0	0	0	0	1	0	0	0	1	1	1	0	1	5
Head and Neck	0	0	0	0	0	0	1	1	0	1	0	1	0	1	1	6
Esophagus	0	0	0	0	0	0	0	1	0	2	4	3	5	5	4	24
Stomach	0	0	0	0	0	0	0	0	1	2	2	1	5	9	10	30
Colon	0	0	0	0	0	0	0	1	3	5	8	11	9	25	26	88
Rectum	0	0	0	0	0	1	0	2	0	1	0	2	5	4	7	22
Liver	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	4
Gall Bladder and Biliary Tract	0	0	0	0	0	0	0	0	1	0	2	2	0	3	3	11
Pancreas	0	0	0	0	0	0	0	0	4	2	3	5	8	7	12	41
Digestive Tract	0	0	0	0	0	0	1	0	0	2	1	1	3	6	7	21
Larynx	0	0	0	0	0	0	0	0	2	2	2	2	4	1	1	14
Trachea, Bronchus and Lung	0	0	0	0	0	1	1	6	8	16	23	33	49	59	61	257
Respiratory System	0	0	0	0	0	0	1	0	0	1	0	2	0	0	0	4
Bone and Connective Tissue	0	2	0	0	1	0	1	0	1	0	1	2	1	1	2	12
Malignant Melanoma of Skin	0	0	0	1	1	0	1	0	0	1	0	1	2	2	1	10
Breast	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
Prostate	0	0	0	0	0	0	1	1	0	5	12	17	24	44	93	197
Male Genital Organs	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
Kidney	1	0	0	0	0	0	0	0	2	3	1	6	4	3	6	26
Bladder	0	0	0	0	0	0	0	1	2	1	1	4	3	7	19	38
Other Urinary Tract	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
Brain and Central Nervous System	2	0	0	0	0	1	2	2	3	3	3	6	4	3	2	31
Thyroid	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1
Other Endocrine Glands	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	3
Lymphoma	0	0	1	0	1	0	1	2	1	2	3	3	11	6	9	40
Hodgkin's Disease	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	2
Multiple Myeloma	0	0	0	0	0	0	0	1	0	1	1	6	1	4	3	17
Leukemia	1	0	0	0	1	1	2	0	5	0	4	2	4	7	12	39
Primary Unknown	0	1	0	0	0	1	2	2	3	1	4	8	14	14	24	74
Other Primaries	0	0	0	0	0	0	0	0	0	1	0	1	2	1	1	6
TOTALS	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	16	21	37	53	76	121	163	215	307	[illegible]
Non-Melanoma Skin Cancer	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	4
Other: In Situ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TOTALS	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

INCIDENCE -- AGE-SPECIFIC RATES per 100,000 (FEMALE) -- 2000

SITE	AGE GROUPS															
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	3.5	0.0	0.0	5.2	0.0	11.5	10.8	1.6
Oral Cavity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	10.1	10.4	10.6	17.3	18.0	2.9
Head and Neck	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.9	0.0	0.0	0.0	25.9	0.0	5.8	0.0	1.6
Esophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	4.5	0.0	15.5	21.1	0.0	3.6	1.9
Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	10.4	4.5	10.1	25.9	47.5	46.1	32.3	7.4
Colon	0.0	0.0	0.0	0.0	0.0	7.6	5.0	23.0	31.2	40.1	55.5	103.6	211.0	126.7	265.9	38.5
Rectum	0.0	0.0	0.0	0.0	0.0	2.5	2.5	20.2	20.8	26.8	20.2	46.6	42.2	97.9	89.8	16.3
Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	5.0	0.0	21.1	5.8	3.6	1.6
Gall Bladder and Biliary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	20.2	10.4	10.6	11.5	32.3	3.9
Pancreas	0.0	0.0	0.0	3.1	0.0	2.5	5.0	5.8	0.0	8.9	25.2	31.1	42.2	23.0	43.1	8.4
Digestive Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	10.4	5.3	0.0	0.0	0.8
Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	5.0	5.2	5.3	17.3	3.6	1.6
Trachea, Bronchus and Lung	0.0	0.0	0.0	3.1	0.0	0.0	2.5	20.2	55.5	115.9	141.4	238.3	248.0	230.3	129.3	48.2
Respiratory System	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	5.0	5.2	10.6	0.0	3.6	1.2
Bone and Connective Tissue	0.0	2.5	0.0	3.1	0.0	0.0	2.5	0.0	3.5	13.4	0.0	5.2	5.3	5.8	10.8	2.5
Malignant Melanoma of Skin	0.0	2.5	5.5	0.0	3.1	12.6	12.6	25.9	13.9	13.4	15.1	41.4	21.1	23.0	32.3	11.3
Breast	0.0	0.0	2.8	6.3	15.6	58.1	93.1	155.6	225.5	240.8	368.5	274.5	395.7	368.5	348.5	117.2
Cervix: Invasive	0.0	0.0	0.0	9.4	28.1	20.2	20.1	11.5	6.9	13.4	10.1	0.0	0.0	17.3	3.6	8.4
Uterus	0.0	0.0	5.5	0.0	3.1	2.5	10.1	31.7	41.6	62.4	75.7	72.5	79.1	74.8	50.3	22.5
Ovary	0.0	2.5	0.0	0.0	21.9	5.1	2.5	14.4	24.3	26.8	20.2	25.9	68.6	40.3	57.5	14.4
Female Genital Organs	0.0	0.0	0.0	3.1	0.0	2.5	5.0	2.9	3.5	8.9	0.0	25.9	5.3	11.5	21.6	4.3
Kidney	0.9	0.0	0.0	0.0	6.2	0.0	0.0	11.5	3.5	17.8	25.2	15.5	31.7	51.8	32.3	8.8
Bladder	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	13.9	17.8	10.1	20.7	47.5	46.1	46.7	8.7
Other Urinary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.2
Brain and Central Nervous System	1.9	5.1	0.0	0.0	0.0	0.0	2.5	2.9	13.9	13.4	20.2	25.9	10.6	23.0	3.6	5.8
Thyroid	0.0	7.6	5.5	3.1	21.9	12.6	20.1	17.3	17.3	13.4	0.0	10.4	0.0	17.3	3.6	8.9
Other Endocrine Glands	0.0	0.0	0.0	0.0	3.1	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4
Lymphoma	0.0	2.5	2.8	0.0	0.0	2.5	10.1	11.5	27.8	40.1	50.5	82.9	63.3	57.6	75.4	18.9
Hodgkin's Disease	0.9	5.1	5.5	6.3	0.0	0.0	2.5	8.6	3.5	0.0	0.0	5.2	5.3	5.8	0.0	2.9
Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	3.5	0.0	5.0	10.4	21.1	23.0	25.1	4.1
Leukemia	1.9	0.0	2.8	0.0	6.2	5.1	7.6	2.9	6.9	31.2	5.0	31.1	47.5	80.6	46.7	12.2
Primary Unknown	0.0	0.0	0.0	0.0	0.0	5.1	5.0	0.0	17.3	31.2	25.2	57.0	36.9	51.8	97.0	14.8
Other Primaries	1.9	0.0	0.0	0.0	0.0	0.0	0.0	5.8	6.9	8.9	10.1	15.5	10.6	5.8	14.4	3.9
TOTALS - ALL SITES																

MORTALITY – AGE-SPECIFIC NUMBERS (MALE) – 2000

SITE	AGE GROUPS														
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
Oral Cavity	0	0	0	0	0	0	1	0	0	0	1	1	1	0	1	5
Head and Neck	0	0	0	0	0	0	1	1	0	1	0	1	0	1	1	6
Esophagus	0	0	0	0	0	0	0	1	0	2	4	3	5	5	4	24
Stomach	0	0	0	0	0	0	0	0	1	2	2	1	5	9	10	30
Colon	0	0	0	0	0	0	0	1	3	5	8	11	9	25	26	88
Rectum	0	0	0	0	0	1	0	2	0	1	0	2	5	4	7	22
Liver	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	4
Gall Bladder and Biliary Tract	0	0	0	0	0	0	0	0	1	0	2	2	0	3	3	11
Pancreas	0	0	0	0	0	0	0	0	4	2	3	5	8	7	12	41
Digestive Tract	0	0	0	0	0	0	1	0	0	2	1	1	3	6	7	21
Larynx	0	0	0	0	0	0	0	0	2	2	2	2	4	1	1	14
Trachea, Bronchus and Lung	0	0	0	0	0	1	1	6	8	16	23	33	49	59	61	257
Respiratory System	0	0	0	0	0	0	1	0	0	1	0	2	0	0	0	4
Bone and Connective Tissue	0	2	0	0	1	0	1	0	1	0	1	2	1	1	2	12
Malignant Melanoma of Skin	0	0	0	1	1	0	1	0	0	1	0	1	2	2	1	10
Breast	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
Prostate	0	0	0	0	0	0	1	1	0	5	12	17	24	44	93	197
Male Genital Organs	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
Kidney	1	0	0	0	0	0	0	0	2	3	1	6	4	3	6	26
Bladder	0	0	0	0	0	0	0	1	2	1	1	4	3	7	19	38
Other Urinary Tract	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
Brain and Central Nervous System	2	0	0	0	0	1	2	2	3	3	3	6	4	3	2	31
Thyroid	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1
Other Endocrine Glands	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	3
Lymphoma	0	0	1	0	1	0	1	2	1	2	3	3	11	6	9	40
Hodgkin's Disease	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	2
Multiple Myeloma	0	0	0	0	0	0	0	1	0	1	1	6	1	4	3	17
Leukemia	1	0	0	0	1	1	2	0	5	0	4	2	4	7	12	39
Primary Unknown	0	1	0	0	0	1	2	2	3	1	4	8	14	14	24	74
Other Primaries	0	0	0	0	0	0	0	0	0	1	0	1	2	1	1	6
TOTALS	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Non-Melanoma Skin Cancer	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	4
Other: In Situ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TOTALS	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●

MORTALITY -- AGE-SPECIFIC NUMBERS (FEMALE) -- 2000

SITE	AGE GROUPS														
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Oral Cavity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	6
Head and Neck	0	0	0	0	0	0	0	0	0	0	2	1	0	1	0	4
Esophagus	0	0	0	0	0	0	0	1	0	1	1	3	1	0	1	8
Stomach	0	0	0	0	0	0	0	2	2	0	1	4	7	4	11	31
Colon	0	0	0	0	0	0	1	1	3	3	4	9	15	11	37	84
Rectum	0	0	0	0	0	0	1	0	0	1	1	2	4	1	14	24
Liver	0	0	0	0	0	0	0	1	0	0	1	0	1	0	1	4
Gall Bladder and Biliary Tract	0	0	0	0	0	0	1	0	0	0	1	2	0	0	4	8
Pancreas	0	0	0	0	0	1	2	2	2	2	5	5	9	2	24	54
Digestive Tract	0	0	0	0	0	0	0	2	0	1	1	1	3	4	8	20
Larynx	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	2
Trachea, Bronchus and Lung	0	0	0	0	0	0	1	4	10	14	16	33	47	41	48	214
Respiratory System	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	3
Bone and Connective Tissue	2	2	0	0	0	0	0	1	0	1	0	0	1	2	0	9
Malignant Melanoma of Skin	0	0	0	0	0	0	1	1	0	0	1	0	0	0	1	4
Breast	0	0	0	0	0	8	8	7	11	11	13	14	20	20	33	145
Cervix: Invasive	1	0	0	1	0	0	0	3	1	3	1	0	2	1	3	16
Uterus	0	0	0	0	0	1	0	1	1	0	2	1	4	1	7	18
Ovary	0	0	0	0	0	3	1	2	2	4	6	2	6	6	19	51
Female Genital Organs	0	0	0	0	0	0	0	0	0	1	0	1	2	1	4	9
Kidney	0	0	0	0	0	0	0	0	2	2	2	3	0	5	13	27
Bladder	0	0	0	0	0	0	0	0	0	0	0	1	1	1	6	9
Other Urinary Tract	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Brain and Central Nervous System	2	0	0	0	1	0	3	1	1	1	5	4	2	3	2	25
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Other Endocrine Glands	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2
Lymphoma	0	1	0	0	0	0	1	2	1	1	1	11	5	7	15	45
Hodgkin's Disease	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	2
Multiple Myeloma	0	0	0	0	0	0	0	0	0	1	2	2	2	7	5	19
Leukemia	0	0	0	0	1	2	1	0	3	1	0	2	5	4	24	43
Primary Unknown	0	0	0	0	0	3	1	1	3	3	3	11	13	16	32	86
Other Primaries	0	0	0	0	0	0	0	0	0	1	1	2	1	1	1	7
TOTALS	6	3	0	1	3	18	22	32	43	52	73	115	151	139	324	982
Non-Melanoma Skin Cancer	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	3
Cervix: In Situ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other: In Situ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
TOTALS	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3	4

MORTALITY -- AGE-SPECIFIC RATES per 100,000 (MALE) -- 2000

SITE	AGE GROUPS															
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.2
Oral Cavity	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	5.2	5.4	6.0	0.0	6.3	1.0
Head and Neck	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.8	0.0	4.4	0.0	5.4	0.0	7.5	6.3	1.2
Esophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	8.8	20.8	16.3	30.2	37.3	25.3	4.7
Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	8.8	10.4	5.4	30.2	67.1	63.2	5.9
Colon	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	10.2	22.1	41.6	59.7	54.4	186.3	164.4	17.3
Rectum	0.0	0.0	0.0	0.0	0.0	2.5	0.0	5.5	0.0	4.4	0.0	10.8	30.2	29.8	44.3	4.3
Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4	6.3	0.8
Gall Bladder and Biliary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	10.4	10.8	0.0	22.4	19.0	2.2
Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.6	8.8	15.6	27.1	48.3	52.2	75.9	8.1
Digestive Tract	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	8.8	5.2	5.4	18.1	44.7	44.3	4.1
Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8	8.8	10.4	10.8	24.2	7.5	6.3	2.8
Trachea, Bronchus and Lung	0.0	0.0	0.0	0.0	0.0	2.5	2.5	16.6	27.2	70.8	119.6	179.0	296.1	439.7	385.8	50.7
Respiratory System	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	4.4	0.0	10.8	0.0	0.0	0.0	0.8
Bone and Connective Tissue	0.0	4.8	0.0	0.0	3.1	0.0	2.5	0.0	3.4	0.0	5.2	10.8	6.0	7.5	12.6	2.4
Malignant Melanoma of Skin	0.0	0.0	0.0	3.0	3.1	0.0	2.5	0.0	0.0	4.4	0.0	5.4	12.1	14.9	6.3	2.0
Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.2
Prostate	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.8	0.0	22.1	62.4	92.2	145.0	327.9	588.1	38.8
Male Genital Organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.2
Kidney	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8	13.3	5.2	32.5	24.2	22.4	37.9	5.1
Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	6.8	4.4	5.2	21.7	18.1	52.2	120.2	7.5
Other Urinary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.2
Brain and Central Nervous System	1.8	0.0	0.0	0.0	0.0	2.5	5.0	5.5	10.2	13.3	15.6	32.5	24.2	22.4	12.6	6.1
Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2
Other Endocrine Glands	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	6.0	0.0	6.3	0.6
Lymphoma	0.0	0.0	2.6	0.0	3.1	0.0	2.5	5.5	3.4	8.8	15.6	16.3	66.5	44.7	56.9	7.9
Hodgkin's Disease	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4
Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	4.4	5.2	32.5	6.0	29.8	19.0	3.4
Leukemia	0.9	0.0	0.0	0.0	3.1	2.5	5.0	0.0	17.0	0.0	20.8	10.8	24.2	52.2	75.9	7.7
Primary Unknown	0.0	2.4	0.0	0.0	0.0	2.5	5.0	5.5	10.2	4.4	20.8	43.4	84.6	104.3	151.8	14.6
Other Primaries	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	5.4	12.1	7.5	6.3	1.2
TOTALS - ALL SITES	202.5															

MORTALITY -- AGE-SPECIFIC NUMBERS (FEMALE) -- 2000

SITE	AGE GROUPS														
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Oral Cavity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	6
Head and Neck	0	0	0	0	0	0	0	0	0	0	2	1	0	1	0	4
Esophagus	0	0	0	0	0	0	0	1	0	1	1	3	1	0	1	8
Stomach	0	0	0	0	0	0	0	2	2	0	1	4	7	4	11	31
Colon	0	0	0	0	0	0	1	1	3	3	4	9	15	11	37	84
Rectum	0	0	0	0	0	0	1	0	0	1	1	2	4	1	14	24
Liver	0	0	0	0	0	0	0	1	0	0	1	0	1	0	1	4
Gall Bladder and Biliary Tract	0	0	0	0	0	0	1	0	0	0	1	2	0	0	4	8
Pancreas	0	0	0	0	0	1	2	2	2	2	5	5	9	2	24	54
Digestive Tract	0	0	0	0	0	0	0	2	0	1	1	1	3	4	8	20
Larynx	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	2
Trachea, Bronchus and Lung	0	0	0	0	0	0	1	4	10	14	16	33	47	41	48	214
Respiratory System	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	3
Bone and Connective Tissue	2	2	0	0	0	0	0	1	0	1	0	0	1	2	0	9
Malignant Melanoma of Skin	0	0	0	0	0	0	1	1	0	0	1	0	0	0	1	4
Breast	0	0	0	0	0	8	8	7	11	11	13	14	20	20	33	145
Cervix: Invasive	1	0	0	1	0	0	0	3	1	3	1	0	2	1	3	16
Uterus	0	0	0	0	0	1	0	1	1	0	2	1	4	1	7	18
Ovary	0	0	0	0	0	3	1	2	2	4	6	2	6	6	19	51
Female Genital Organs	0	0	0	0	0	0	0	0	0	1	0	1	2	1	4	9
Kidney	0	0	0	0	0	0	0	0	2	2	2	3	0	5	13	27
Bladder	0	0	0	0	0	0	0	0	0	0	0	1	1	1	6	9
Other Urinary Tract	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Brain and Central Nervous System	2	0	0	0	1	0	3	1	1	1	5	4	2	3	2	25
Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Other Endocrine Glands	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2
Lymphoma	0	1	0	0	0	0	1	2	1	1	1	11	5	7	15	45
Hodgkin's Disease	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	2
Multiple Myeloma	0	0	0	0	0	0	0	0	0	1	2	2	2	7	5	19
Leukemia	0	0	0	0	1	2	1	0	3	1	0	2	5	4	24	43
Primary Unknown	0	0	0	0	0	3	1	1	3	3	3	11	13	16	32	86
Other Primaries	0	0	0	0	0	0	0	0	0	1	1	2	1	1	1	7
TOTALS	●	●	●	●	●	18	18	24	35	52	70	105	151	130	329	●
Non-Melanoma Skin Cancer	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	3
Cervix: In Situ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other: In Situ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
TOTALS	●	●	●	●	●	●	1	●	●	●	●	●	●	●	●	●

MORTALITY -- AGE-SPECIFIC RATES per 100,000 (MALE) -- 2000

SITE	AGE GROUPS															
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.2
Oral Cavity	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	5.2	5.4	6.0	0.0	6.3	1.0
Head and Neck	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.8	0.0	4.4	0.0	5.4	0.0	7.5	6.3	1.2
Esophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	8.8	20.8	16.3	30.2	37.3	25.3	4.7
Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	8.8	10.4	5.4	30.2	67.1	63.2	5.9
Colon	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	10.2	22.1	41.6	59.7	54.4	186.3	164.4	17.3
Rectum	0.0	0.0	0.0	0.0	0.0	2.5	0.0	5.5	0.0	4.4	0.0	10.8	30.2	29.8	44.3	4.3
Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4	6.3	0.8
Gall Bladder and Biliary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	10.4	10.8	0.0	22.4	19.0	2.2
Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.6	8.8	15.6	27.1	48.3	52.2	75.9	8.1
Digestive Tract	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	8.8	5.2	5.4	18.1	44.7	44.3	4.1
Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8	8.8	10.4	10.8	24.2	7.5	6.3	2.8
Trachea, Bronchus and Lung	0.0	0.0	0.0	0.0	0.0	2.5	2.5	16.6	27.2	70.8	119.6	179.0	296.1	439.7	385.8	50.7
Respiratory System	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	4.4	0.0	10.8	0.0	0.0	0.0	0.8
Bone and Connective Tissue	0.0	4.8	0.0	0.0	3.1	0.0	2.5	0.0	3.4	0.0	5.2	10.8	6.0	7.5	12.6	2.4
Malignant Melanoma of Skin	0.0	0.0	0.0	3.0	3.1	0.0	2.5	0.0	0.0	4.4	0.0	5.4	12.1	14.9	6.3	2.0
Breast	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.2
Prostate	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.8	0.0	22.1	62.4	92.2	145.0	327.9	588.1	38.8
Male Genital Organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.2
Kidney	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8	13.3	5.2	32.5	24.2	22.4	37.9	5.1
Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	6.8	4.4	5.2	21.7	18.1	52.2	120.2	7.5
Other Urinary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.2
Brain and Central Nervous System	1.8	0.0	0.0	0.0	0.0	2.5	5.0	5.5	10.2	13.3	15.6	32.5	24.2	22.4	12.6	6.1
Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2
Other Endocrine Glands	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	6.0	0.0	6.3	0.6
Lymphoma	0.0	0.0	2.6	0.0	3.1	0.0	2.5	5.5	3.4	8.8	15.6	16.3	66.5	44.7	56.9	7.9
Hodgkin's Disease	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4
Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	4.4	5.2	32.5	6.0	29.8	19.0	3.4
Leukemia	0.9	0.0	0.0	0.0	3.1	2.5	5.0	0.0	17.0	0.0	20.8	10.8	24.2	52.2	75.9	7.7
Primary Unknown	0.0	2.4	0.0	0.0	0.0	2.5	5.0	5.5	10.2	4.4	20.8	43.4	84.6	104.3	151.8	14.8
Other Primaries	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	5.4	12.1	7.5	6.3	1.2
TOTALS - ALL SITES																

MORTALITY -- AGE-SPECIFIC RATES per 100,000 (FEMALE) -- 2000

SITE	AGE GROUPS														
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Oral Cavity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.6	1.2
Head and Neck	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.1	5.2	0.0	5.8	0.0	0.8
Esophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	4.5	5.0	15.5	5.3	0.0	3.6	1.6
Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	6.9	0.0	5.0	20.7	36.9	23.0	39.5	6.0
Colon	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.9	10.4	13.4	20.2	46.6	79.1	63.3	132.9	16.3
Rectum	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	4.5	5.0	10.4	21.1	5.8	50.3	4.7
Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	5.0	0.0	5.3	0.0	3.6	0.8
Gall Bladder and Biliary Tract	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	5.0	10.4	0.0	0.0	14.4	1.6
Pancreas	0.0	0.0	0.0	0.0	0.0	2.5	5.0	5.8	6.9	8.9	25.2	25.9	47.5	11.5	86.2	10.5
Digestive Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	0.0	4.5	5.0	5.2	15.8	23.0	28.7	3.9
Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	3.6	0.4
Trachea, Bronchus and Lung	0.0	0.0	0.0	0.0	0.0	0.0	2.5	11.5	34.7	62.4	80.8	170.9	248.0	236.0	172.5	41.6
Respiratory System	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	5.2	0.0	0.0	3.6	0.6
Bone and Connective Tissue	1.9	5.1	0.0	0.0	0.0	0.0	0.0	2.9	0.0	4.5	0.0	0.0	5.3	11.5	0.0	1.7
Malignant Melanoma of Skin	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.9	0.0	0.0	5.0	0.0	0.0	0.0	3.6	0.8
Breast	0.0	0.0	0.0	0.0	0.0	20.2	20.1	20.2	38.2	49.0	65.6	72.5	105.5	115.1	118.6	28.2
Cervix Invasive	0.9	0.0	0.0	3.1	0.0	0.0	0.0	8.6	3.5	13.4	5.0	0.0	10.6	5.8	10.8	3.1
Uterus	0.0	0.0	0.0	0.0	0.0	2.5	0.0	2.9	3.5	0.0	10.1	5.2	21.1	5.8	25.1	3.5
Ovary	0.0	0.0	0.0	0.0	0.0	7.6	2.5	5.8	6.9	17.8	30.3	10.4	31.7	34.5	68.3	9.9
Female Genital Organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	5.2	10.6	5.8	14.4	1.7
Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	8.9	10.1	15.5	0.0	28.8	46.7	5.2
Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	5.3	5.8	21.6	1.7
Other Urinary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brain and Central Nervous System	1.9	0.0	0.0	0.0	3.1	0.0	7.6	2.9	3.5	4.5	25.2	20.7	10.6	17.3	7.2	4.9
Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.2
Other Endocrine Glands	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.4
Lymphoma	0.0	2.5	0.0	0.0	0.0	0.0	2.5	5.8	3.5	4.5	5.0	57.0	26.4	40.3	53.9	8.7
Hodgkin's Disease	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	3.6	0.4
Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	10.1	10.4	10.6	40.3	18.0	3.7
Leukemia	0.0	0.0	0.0	0.0	3.1	5.1	2.5	0.0	10.4	4.5	0.0	10.4	26.4	23.0	86.2	8.4
Primary Unknown	0.0	0.0	0.0	0.0	0.0	7.6	2.5	2.9	10.4	13.4	15.1	57.0	68.6	92.1	115.0	16.7
Other Primaries	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	5.0	10.4	5.3	5.8	3.6	1.4
TOTALS - ALL SITES	190.8															

MORTALITY -- AGE-SPECIFIC RATES per 100,000 (FEMALE) -- 2000

SITE	AGE GROUPS															
	0-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	All Ages
Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Oral Cavity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.6	1.2
Head and Neck	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.1	5.2	0.0	5.8	0.0	0.8
Esophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	4.5	5.0	15.5	5.3	0.0	3.6	1.6
Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	6.9	0.0	5.0	20.7	36.9	23.0	39.5	6.0
Colon	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.9	10.4	13.4	20.2	46.6	79.1	63.3	132.9	16.3
Rectum	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	4.5	5.0	10.4	21.1	5.8	50.3	4.7
Liver	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	5.0	0.0	5.3	0.0	3.6	0.8
Gall Bladder and Biliary Tract	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	5.0	10.4	0.0	0.0	14.4	1.6
Pancreas	0.0	0.0	0.0	0.0	0.0	2.5	5.0	5.8	6.9	8.9	25.2	25.9	47.5	11.5	86.2	10.5
Digestive Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	0.0	4.5	5.0	5.2	15.8	23.0	28.7	3.9
Larynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	3.6	0.4
Trachea, Bronchus and Lung	0.0	0.0	0.0	0.0	0.0	0.0	2.5	11.5	34.7	62.4	80.8	170.9	248.0	236.0	172.5	41.8
Respiratory System	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	5.2	0.0	0.0	3.6	0.6
Bone and Connective Tissue	1.9	5.1	0.0	0.0	0.0	0.0	0.0	2.9	0.0	4.5	0.0	0.0	5.3	11.5	0.0	1.7
Malignant Melanoma of Skin	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.9	0.0	0.0	5.0	0.0	0.0	0.0	3.6	0.8
Breast	0.0	0.0	0.0	0.0	0.0	20.2	20.1	20.2	38.2	49.0	65.6	72.5	105.5	115.1	118.6	28.2
Cervix: Invasive	0.9	0.0	0.0	3.1	0.0	0.0	0.0	8.6	3.5	13.4	5.0	0.0	10.6	5.8	10.8	3.1
Uterus	0.0	0.0	0.0	0.0	0.0	2.5	0.0	2.9	3.5	0.0	10.1	5.2	21.1	5.8	25.1	3.5
Ovary	0.0	0.0	0.0	0.0	0.0	7.6	2.5	5.8	6.9	17.8	30.3	10.4	31.7	34.5	68.3	9.9
Female Genital Organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	5.2	10.6	5.8	14.4	1.7
Kidney	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	8.9	10.1	15.5	0.0	28.8	46.7	5.2
Bladder	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	5.3	5.8	21.6	1.7
Other Urinary Tract	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Brain and Central Nervous System	1.9	0.0	0.0	0.0	3.1	0.0	7.6	2.9	3.5	4.5	25.2	20.7	10.6	17.3	7.2	4.9
Thyroid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.2
Other Endocrine Glands	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.4
Lymphoma	0.0	2.5	0.0	0.0	0.0	0.0	2.5	5.8	3.5	4.5	5.0	57.0	26.4	40.3	53.9	8.7
Hodgkin's Disease	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	3.6	0.4
Multiple Myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	10.1	10.4	10.6	40.3	18.0	3.7
Leukemia	0.0	0.0	0.0	0.0	3.1	5.1	2.5	0.0	10.4	4.5	0.0	10.4	26.4	23.0	86.2	8.4
Primary Unknown	0.0	0.0	0.0	0.0	0.0	7.6	2.5	2.9	10.4	13.4	15.1	57.0	68.6	92.1	115.0	16.7
Other Primaries	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	5.0	10.4	5.3	5.8	3.6	1.4
TOTALS - ALL SITES	[illegible]															

PROVINCIAL INCIDENCE
1970 - 2000



NUMBER OF CASES
1970 - 2000



NON-MELANOMA SKIN AND IN-SITU CASE EXCLUDED

PEDIATRIC INCIDENCE -- 2000 -- Both Clinics

SITE AGE GROUPS

Public Information Available

- Annual Report
- Saskatchewan Cancer Agency Brochures
- List of Payees

PEDIATRIC INCIDENCE – 2000 – Both Clinics

SITE		AGE GROUPS					
		<1	1-4	5-9	10-14	15-19	TOTAL
Bone	M	0	0	0	1	2	3
	F	0	0	0	0	0	0
Soft Tissue	M	0	0	0	0	0	0
	F	0	0	0	0	1	1
Wilm's Tumor	M	0	0	0	0	0	0
	F	1	0	0	0	0	1
Gonadal/Germ	M	0	0	0	0	0	0
Cell Tumors	F	0	0	0	0	1	1
Retinoblastoma	M	1	0	0	0	0	1
	F	2	0	0	0	0	2
Brain, CNS	M	0	0	1	1	2	4
	F	0	1	1	0	2	4
Lymphoma	M	1	0	1	0	6	8
	F	0	0	0	1	3	4
Leukemia	M	0	2	3	2	0	7
	F	0	1	1	0	0	2
Other	M	0	1	0	0	0	1
	F	0	0	0	0	4	4
TOTALS	M	2	3	5	4	10	24
	F	3	2	2	1	11	19

Public Information Available

- **Annual Report**
- **Saskatchewan Cancer Agency Brochures**
- **List of Payees**

Report of Management

Mangement is resonsible for the integrity of the financial data reported by the Foundation. Fulfilling this responsibility requires the preparation and presentation of financial statements, in accordance with Canadian generally accepted accounting principles which are consistently applied, with any exceptions specifically described in the financial statements.

Management uses internal accounting controls, offers direction through Foundation-wide policies and procedures and exercises its best judgement in order that the statements reflect fairly the financial position, results of operations and changes in financial position.

In order to gather and control financial data, the Foundation has established accounting and reporting systems supported by internal controls. In establishing systems of internal control, management weighs the cost of such systems against the benefits that it believes can be obtained. Management believes that the existing controls provide reasonable assurance that assets are safe-guarded and that the financial records are reliable for preparing statements and other data and maintaining accountability for assets.

The Provincial Auditor has examined the Saskatchewan Cancer Foundation's statement of financial position as at March 31, 2001 and the statements of operations and changes in fund balances and cash flows for the year then ended. Their responsbility is to express an opinion on the fairness of management's financial statements. The Auditor's Report outlines the scope of their audit and their opinion.

On behalf of Management.

Robert D. Allen
Chief Executive Officer

Kevin A. Lacey, CA
Executive Director, Finance

AUDITOR'S REPORT

To the Members of the Legislative Assembly of Saskatchewan

I have audited the statement of financial position of the Saskatchewan Cancer Foundation as at March 31, 2001 and the statements of operations and changes in fund balances, and cash flows for the year then ended. The Foundation's management is responsible for preparing these financial statements for Treasury Board's approval. My responsibility is to express an opinion on these financial statements based on my audit.

I conducted my audit in accordance with Canadian generally accepted auditing standards. Those standards require that I plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In my opinion, these financial statements present fairly, in all material respects, the financial position of the Foundation as at March 31, 2001 and the results of its operations and its cash flows for the year then ended in accordance with Canadian generally accepted accounting principles.

Regina, Saskatchewan
May 9, 2001

Fred Wendel, CMA, CA
Acting Provincial Auditor

Statement 1

SASKATCHEWAN CANCER FOUNDATION
STATEMENT OF FINANCIAL POSITION
As at March 31

	2001						2000
	Operating Funds		Restricted Funds				
	Operating Fund	Division of Prevention & Early Detection	Capital Fund	Research Fund	Trust Fund	Total	Total
ASSETS							
Current Assets:							
Cash and short-term investments (Schedule 2)	$ 704,134	$ 844,050	$ 3,638,636	$ 155,849	$ 734,341	$ 6,077,010	$ 5,483,622
Accounts receivable:							
Saskatchewan Health -General Revenue Fund	225,560	—	3,085,000	—	—	3,310,560	—
Other and accrued interest	168,900	35,531	11,239	156,202	27,802	399,674	498,134
Prepaid expenses	98,446	—	899,999	7,901	95	1,006,441	91,039
Due (to) from other funds	464,651	(573,564)	108,242	(23,819)	24,490	—	—
	1,661,691	306,017	7,743,116	296,133	786,728	10,793,685	6,072,795
Investments (Schedule 2)							
(Market $10,830,030; 2000 - $11,375,341)	7,248,010	1,979,980	489,650	—	1,024,500	10,742,140	11,638,460
Capital Assets (Note 3)	—	—	21,478,079	—	—	21,478,079	20,530,747
	$ 8,909,701	$ 2,285,997	$ 29,710,845	$ 296,133	$ 1,811,228	$ 43,013,904	$ 38,242,002
LIABILITIES AND FUND BALANCES							
Current Liabilities:							
Accounts payable:							
Trade	$ 2,487,060	$ 151,527	$ 386,145	$ 1,112	$ 3,583	$ 3,029,427	$ 2,507,841
Vacation	460,361	4,581	—	—	—	464,942	452,988
Deferred revenue	486,950	—	—	—	—	486,950	839,936
	3,434,371	156,108	386,145	1,112	3,583	3,981,319	3,800,765
Fund Balances:							
Invested in capital assets	—	—	21,478,079	—	—	21,478,079	20,530,747
Other capital fund net assets	—	—	7,846,621	—	—	7,846,621	4,765,306
Externally restricted, statement 2	—	—	—	295,021	1,807,645	2,102,666	1,458,316
Unrestricted, statement 2	5,475,330	2,129,889	—	—	—	7,605,219	7,686,868
	5,475,330	2,129,889	29,324,700	295,021	1,807,645	39,032,585	34,441,237
	$ 8,909,701	$ 2,285,997	$ 29,710,845	$ 296,133	$ 1,811,228	$ 43,013,904	$ 38,242,002

(See accompanying notes to the financial statements)

Statement 2

SASKATCHEWAN CANCER FOUNDATION
STATEMENT OF OPERATIONS AND CHANGES IN FUND BALANCES
Year ended March 31

	Operating Funds				Restricted Funds				
	Operating Fund	Division of Prevention & Early Detection	Total 2001	Total 2000	Capital Fund	Research Fund	Trust Fund	Total 2001	Total 2000
Revenues:									
Saskatchewan Health - General Revenue Fund	$ 32,929,495	$ 2,074,025	$ 35,003,520	$ 32,097,128	$ 6,085,000	$ 345,000	$ —	$ 6,430,000	$ 1,851,314
Grants	—	—	—	—	—	355,073	—	355,073	325,478
Donations and bequests	—	—	—	—	—	—	687,812	687,812	306,682
Other income	831,482	63,706	895,188	920,236	17,833	171,514	—	189,347	334,633
	33,760,977	2,137,731	35,898,708	33,017,364	6,102,833	871,587	687,812	7,662,232	2,818,107
Expenses:									
Divisions and general administration									
Salaries and employee benefits	19,018,662	1,250,354	20,269,016	18,116,925	—	—	—	—	—
Drugs and medical supplies	9,920,339	—	9,920,339	8,182,217	—	—	—	—	—
Purchased services	1,644,033	—	1,644,033	1,530,522	—	—	—	—	—
Other operating expenditures	3,651,209	836,703	4,487,912	4,022,757	—	—	171,838	171,838	56,155
Research grants (Schedule 1)	—	—	—	—	—	1,007,950	—	1,007,950	959,157
Trust fund grants	—	—	—	—	—	—	2,016	2,016	48,045
	34,234,243	2,087,057	36,321,300	31,852,421	—	1,007,950	173,854	1,181,804	1,063,357
	(473,266)	50,674	(422,592)	1,164,943	6,102,833	(136,363)	513,958	6,480,428	1,754,750
Investment income	643,610	119,651	763,261	797,851	201,797	17,127	89,640	308,564	188,318
	170,344	170,325	340,669	1,962,794	6,304,630	(119,236)	603,598	6,788,992	1,943,068
Less amortization expense	—	—	—	—	2,538,313	—	—	2,538,313	2,421,692
Excess (deficiency) of revenues over expenses	170,344	170,325	340,669	1,962,794	3,766,317	(119,236)	603,598	4,250,679	(478,624)
Fund balances, beginning of year	5,694,477	1,992,391	7,686,868	7,830,108	25,296,053	149,883	1,308,433	26,754,369	25,126,959
Interfund transfers (Note 10)	(389,491)	(32,827)	(422,318)	(2,106,034)	262,330	264,374	(104,386)	422,318	2,106,034
Fund balances, end of year	$ 5,475,330	$ 2,129,889	$ 7,605,219	$ 7,686,868	$ 29,324,700	$ 295,021	$ 1,807,645	$ 31,427,366	$ 26,754,369

(See accompanying notes to the financial statements)

Statement 3

SASKATCHEWAN CANCER FOUNDATION
STATEMENT OF CASH FLOWS
Year Ended March 31

	2001	2000
Cash resources provided by (used in):		
OPERATING ACTIVITIES:		
Excess (deficiency) of revenues over expenses (Statement 2):		
Operating fund	$ 170,344	$ 1,861,634
Division of Prevention & Early Detection	170,325	101,160
Research fund	(119,236)	55,459
Trust fund	603,598	286,524
	825,031	2,304,777
Net change in non-cash working capital (Note 4)	(3,946,948)	171,424
Net cash (used in) provided by operating activities	(3,121,917)	2,476,201
INVESTMENT ACTIVITIES:		
Net acquisition of capital assets	(3,485,645)	(730,819)
Net acquisition of investments	896,320	(2,019,850)
FINANCING ACTIVITIES:		
Payment from General Revenue Fund for capital assets	6,085,000	1,506,314
Other capital fund activities	219,630	94,771
Net change in cash resources during the year	593,388	1,326,617
Cash and short-term investments, beginning of year	5,483,622	4,157,005
Cash and short-term investments, end of year	$ 6,077,010	$ 5,483,622

(See accompanying notes to the financial statements)

SASKATCHEWAN CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
March 31, 2001

1. Legal Status of the Saskatchewan Cancer Foundation

The Foundation was created under provisions of *The Cancer Foundation Act* and commenced operations on August 1, 1979. The Foundation conducts a program for the treatment and prevention of cancer.

2. Significant Accounting Policies

These financial statements have been prepared in accordance with generally accepted accounting principles and include the following significant policies:

a) Fund accounting

The accounts of the Foundation are maintained in accordance with the principles of fund accouting. For financial reporting purposes, accounts with similar characteristics have been combined into the following major funding groups:

Unrestricted Funds

i) Operating Fund

The Operating Fund reflects the operations of the Allan Blair Cancer Centre, the Saskatoon Cancer Centre, and their representative patient lodges. Also included are research, public education, and communication activities.

The Cancer Centres provide diagnostic services, treatment services in radiotherapy and chemotherapy, and follow-up services. They serve as the focal points for the co-ordination of a comprehensive and multi-disciplinary approach to all aspects of care and treatment for cancer patients. The patient lodges provide housing for rural patients who are undergoing treatment at the Cancer Centres.

Research activities include basic and epidemiological research. Basic research attempts to understand, at the cellular and molecular level, the underlying differences between normal and cancerous cells. Epidemiological research involves studying the distribution and determinants of various cancers in specific populations and the application of these studies to cancer control.

Public education and communications through written, oral, and visual media are integral components of a diverse cancer care program.

ii) Prevention & Early Detection

Prevention and early detection programs in this fund are aimed at minimizing the impact of cancer through prevention and control. The Screening Program for Breast Cancer has responsibility for screening mammography for women ages 50-69 years of age in the Province.

Restricted Funds

iii) Capital Fund

The Capital Fund reflects the equity of the Foundation in capital assets. The Capital Fund includes revenues received from the Department of Health - General Revenue Fund. Expenses are primarily amortization of capital assets.

iv) Research Fund

The Department of Health - General Revenue Fund has provided funding to enable the Foundation to support a number of research projects. The Department of Health has attached the following guidelines to the funds:

a) Expenditure of these funds is at the discretion of the Foundation. The Foundation will assume responsibility for research costs in excess of the amount funded.

b) Research funds, including investment income on the funds, should be kept separate from other funds of the Foundation.

Activities of the fund include clinical trials research which is a scientific method for testing new or combinations of existing treatment modalities against the current standard of treatment for that specific cancer.

v) Trust Fund

The Trust Fund accepts donations for contributions designated by the contributors to be used for such purposes as cancer research, equipment and library books. The Foundation maintains a record of the funds contributed and spent for each of the designated purposes until such funds are fully utilized.

b) Revenue

Unrestricted contributions are recognized as revenue in the Operating Fund in the year received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Restricted contributions related to the general operations are recognized as revenue of the Operating Fund in the year in which the related expenses are incurred. All other restricted contributions are recognized as revenue of the appropriate restricted fund in the year received or receivable.

c) Investments

Investments are valued at the lower of cost or net realizable value.

d) Capital Assets

Capital assets are recorded at cost. Normal maintenance and repairs are expensed as incurred. Capital assets are amortized on a straight-line basis over their estimated useful lives as follows:

Buildings	20 years
Leasehold Alterations	10 - 20 years
Equipment	5 - 10 years

3. Capital Assets

	2001			2000
	Cost	Accumulated Amortization	Net Book Value	Net Book Value
Land & Improvements	$ 280,297	$ ---	$ 280,297	$ 280,297
Buildings	18,236,378	12,304,010	5,932,368	6,841,396
Leasehold Alterations	10,060,733	2,896,781	7,163,952	7,638,342
Equipment & Furniture	23,740,046	15,738,081	8,001,965	5,770,712
Work in Progress	99,497	---	99,497	---
	$ 52,416,951	$ 30,938,872	$ 21,478,079	$ 20,530,747

4. Net Change in Non-Cash Working Capital Balances Related to Operations

	2001	2000
(Increase) decrease in accounts receivable	$ (3,212,100)	$ 100,607
(Increase) decrease in prepaid expenses	(915,402)	38,652
Increase (decrease) in trade accounts payable	521,586	(65,579)
Increase in vacation accrual	11,954	77,423
Increase (decrease) in deferred revenue	(352,986)	20,321
Net change in non-cash working capital balances related to operations	$ (3,946,948)	$ 171,424

5. Pension Plan

The Foundation participates in The Public Employees' Pension Plan (a related party) which is a defined contribution pension plan for the benefit of its employees. The Province of Saskatchewan is responsible for the plan. The Foundation's financial obligation to the plan is limited to making required payments to match the amount contributed by the employees for current services. The Foundation follows defined contribution plan accounting for its participation in the plan. Accordingly, the Foundation expenses all contributions it is required to make in the year. Pension expense for the year amounted to $725,439 (2000 - $669,591) and is included in benefits.

6. Commitments

The Foundation is committed under term leases for office space at the following minimum amounts over the next five years (exclusive of proportionate increases and additional occupancy costs):

2002	$ 153,119
2003	92,647
2004	22,273
2005	---
2006	---

The Foundation has a $3.3 million commitment to complete the purchase and installation of radiation therapy equipment at the Allan Blair Cancer Centre and Saskatoon Cancer Centre during the next fiscal year.

7. Cancer Patient Lodges

The Canadian Cancer Society, Saskatchewan Division, has donated two cancer patient lodges in the Province to the Foundation. Under the terms of an agreement with the Society, the Foundation has assumed responsibility for the operations of these lodges. Title to the properties will remain with the Foundation so long as they are operated as cancer patient lodges.

8. Related Party Transactions

Included in these financial statements are transactions with various Saskatchewan Crown corporations, departments, agencies, boards and commissions related to the Foundation by virtue of common control by the Government of Saskatchewan and non-Crown corporations and enterprises subject to joint control and significant influence by the Government of Saskatchewan (collectively referred to as "related parties").

Drugs and purchased hospital services acquired from related parties are recorded at exchange amounts agreed to by the related parties. These transactions and amounts outstanding at year end are as follows:

	2001	2000
Expenses	$ 14,900,464	$ 12,013,368
Accounts payable	1,643,236	1,994,924

Routine operating transactions with related parties are settled at prevailing market prices under normal trade terms. These transactions and amounts outstanding at year end are as follows:

	2001	2000
Expenses	$ 1,817,632	$ 1,577,718
Accounts payable	123,235	108,633

In addition, the Foundation pays Saskatchewan Education and Health Tax to the Saskatchewan Department of Finance on all its taxable purchases. Taxes paid are recorded as part of the cost of those purchases.

The Regina Clinic is leased from the Regina District Health Board for $1 per year, including a portion of occupancy costs. The Saskatoon Clinic building owned by the Foundation is situated on land not owned by the Foundation. The Foundation is not charged for the use of this land.

Other amounts and transactions with related parties and the terms of settlement are described separately in these financial statements and notes thereto.

9. Financial Instruments

a) Significant terms and conditions

There are no significant terms and conditions related to financial instruments classified as current assets or current liabilities that may affect the amount, timing and certainty of future cash flows.

b) Interest rate risk

The Foundation is exposed to the following interest rate risk when the value of its financial instruments fluctuate due to changes in market interest rates:

- The interest rate risk for the Foundation's receivables and payables is minimal because they are non-interest bearing and of a short-term nature.

- As market interest rates fluctuate, the market value of long-term investments moves in the opposite direction. This risk will affect the selling price of investments if they are sold prior to maturity. Due to the size and nature of the Foundation's investment portfolio and its future cash flow needs, the Foundation is able to manage the timing of investment disposals in a manner that minimizes the interest rate risk.

c) Credit risk

The Foundation is exposed to credit risk from potential non-payment of accounts receivable or investment income and principle. The credit risk for the Foundation's receivables is minimal because they are mostly from the Department of Health - General Revenue Fund or other goverment organizations. The credit risk for the Foundation's investments and related accrued interest receivable is minimal because investments consist of provincial government bonds and debentures, corporate bonds, and guaranteed investment certificates with large Canadian banks.

d) Fair value

The following methods and assumptions were used to estimate the fair value of each class of financial instrument:

- The carrying value of the following financial instruments approximate fair value due to their immediate or short-term nature:

  Cash and short-term investments
  Accounts receivable
  Accounts payable

- For investments, the fair value is considered to approximate quoted market values.

10. Interfund Transfers

Interfund transfers consist of funds transferred from the Operating, Division of Prevention and Early Detection, Research, and Trust Funds to the Capital Fund to finance the purchase of capital assets and funds transferred from the Operating Fund to the Research Fund for research activities.

11. Budgets

Schedule 3 compares actual expenditures to Board approved budgeted expenditures for the year ended March 31, 2001.

Schedule 1

SASKATCHEWAN CANCER FOUNDATION RESEARCH FUND
SCHEDULE OF RESEARCH GRANTS
Year Ended March 31

	2001	2000
Participation in North Central Cancer Treatment Group	$ 548,618	$ 460,906
Participation in Children's Cancer Group	223,648	215,088
Radiation Therapy Oncology Group	41,429	35,580
Cell Surface Characteristics of Metastatic Cells in Human Tumors, Saskatoon	85,375	71,192
Molecular basis of B72.3 Combining Sites and Synthesis, Saskatoon	81,048	53,027
Cranial Irradiation Revisited, Saskatoon	10,550	12,161
Impact of Treatment of Prognostic Variable on Differentiated Thyroid Cancer, Regina	7,835	---
Radiation Treatment Planning for Lung Cancer, Regina	4,453	---
Prostate Cancer Before and During the PSA era, Saskatoon	12,792	---
Research Director Fund, Saskatoon	---	415
Identification of p85 SH2 Binding Proteins, Saskatoon	---	14,319
C-Src and Colon Cancer, Saskatoon	---	17,284
Genomic Instability	---	10,593
Prostate Patient Immobilization	---	1,423
Role of A-Raf-1	---	68,368
Total	1,015,748	960,356
Less capital expenditures	(7,798)	(1,199)
	$ 1,007,950	$ 959,157

(See accompanying notes to the financial statements)

Schedule 2

SASKATCHEWAN CANCER FOUNDATION RESEARCH FUND
SCHEDULE OF INVESTMENTS
Year Ended March 31, 2001

	Carrying Value	Maturity Date	Effective Rate
Cash and short-term investments:			
Cash:			
Royal Bank of Canada	$ 4,798,852	---	4.85%
Short-term investments:			
Investors Dividend Fund	21,802	---	---
Canadian Western Bank GIC	956,356	07/11/01	4.66%
Province of Saskatchewan Savings Bond	300,000	07/15/01	5.50%
	1,278,158		
	6,077,010		
Long-term investments:			
Province of Saskatchewan Savings Bond	100,000	07/15/05	5.75%
Province of Ontario Bond	1,995,200	09/12/07	6.25%
Bell Canada Bond	299,700	01/18/08	6.37%
Province of Saskatchewan Savings Bond	497,000	05/28/08	5.58%
Province of Manitoba Bond	995,000	06/02/08	5.90%
Province of Saskatchewan Savings Bond	489,650	06/02/08	5.88%
Royal Bank of Canada Bond	993,860	06/11/09	5.24%
TD Capital Trust Securities	350,000	12/31/09	7.75%
Province of Nova Scotia Bond	993,900	09/01/10	6.59%
TD Bank Debenture	998,780	07/31/12	6.67%
Bank of Nova Scotia Bond	1,018,500	07/22/13	5.54%
Bank of Nova Scotia Bond	489,250	05/12/14	6.13%
Province of New Brunswick Bond	496,800	12/27/17	6.06%
Province of Newfoundland Debentures	1,024,500	04/17/28	5.97%
	10,742,140		
Total cash and investments	$ 16,819,150		

(See accompanying notes to the financial statements)

Schedule 3

SASKATCHEWAN CANCER FOUNDATION
COMPARISON OF BUDGET TO ACTUAL
Year Ended March 31, 2001

	Operating Fund		Division of Prevention & Early Detection	
	Actual	Budget	Actual	Budget
Revenues:				
Saskatchewan Health - General Revenue Fund	$ 32,929,495	$ 31,203,935	$ 2,074,025	$ 2,074,025
Other income	831,482	915,267	63,706	50,000
	33,760,977	32,119,202	2,137,731	2,124,025
Expenses:				
Salaries & employee benefits	19,018,662	19,954,291	1,250,354	1,389,598
Drugs and medical supplies	9,920,339	8,408,800	---	---
Purchased services	1,644,033	1,568,000	---	---
Other operating expenditures	3,651,209	3,393,303	836,703	854,427
	34,234,243	33,324,394	2,087,057	2,244,025
	(473,266)	(1,205,192)	50,674	(120,000)
Investment income	643,610	550,000	119,651	120,000
Excess (deficiency) of revenues over expenses	$ 170,344	$ (655,192)	$ 170,325	$ ---

(See accompanying notes to the financial statements)

SASKATCHEWAN CANCER AGENCY GRANTS (2000-2001)

Molecular basis of B72.3 combining-sites and humanizing B72.3 antibody by resurfacing the antigenic epitopes under the guidance of molecular modeling - Xiang, J.
Using a computational model of the antibody-antigen complex B72.3/TAG72, 17 complementarity-determining region residues were defined. The model was tested using site-directed mutagenesis and found to be accurate in many of its features suggesting that the computational modeling approach is a useful method to study antigen/antibody complexes. The results from this study should result in the generation of a superior reagent for use in cancer imaging and immunotherapy.

Role of Sialyltransferase-1 in Tumor Metastasis - Carlsen, S.
This project involves delineating some of the unique properties of tumor cells capable of metastasis. Using a rat breast tumor model system, we have identified a series of genes whose expression is specifically turned off in highly metastatic cells. We are currently cloning and characterizing the expression of these genes in a variety of cell types. We have also isolated human homologues of these genes and are currently investigating the mechanisms involved in the regulation of the expression of these genes. This research will hopefully provide new information about what causes cancer cells to metastasize.

Prostate cancer in Saskatchewan, before and during the PSA era: tumor characteristics, treatment and outcomes - Skarsgard, D. and Tonita, J., Tai, P., Visvanathan, K.
The charts of all patients diagnosed with prostate cancer in Saskatchewan over a 15-year period are being reviewed by health records technicians, under the supervision of D. Skarsgard. Information including stage, grade, PSA, first treatment and later development of metastases, will be added to corresponding patient records in the Saskatchewan Cancer Registry to provide a comprehensive picture of tumour characteristics, treatment and outcome. This will allow a description of any changes in the above with the advent of PSA testing, and may give insights into the usefulness of PSA screening. As well, the study will provide population-based outcomes information according to stage, grade, PSA and treatment, which will be useful in counselling individual patients about choice of treatment and prognosis.

Radiation treatment planning for lung cancer: a trans-Canada patterns of practice study - Tai, P., van Dyke, J., Yu, E. and Tonita, J.
The objective of this study is to determine the current practice of radiation treatment for small cell and non-small cell lung cancer subtypes across Canada. The results of this study will help set up a nation-wide standard for lung cancer treatment. A questionnaire has been developed for data collection which will take place in the coming year.

The impact of initial treatment and prognostic variables on differentiated thyroid cancer from Saskatchewan, Canada, 1958-1998 - Mahmud, A. and Tonita, J.
This study is designed to investigate several controversies with respect to the management of thyroid cancer. These include the extent of surgery, treatment of lymph node metastasis, role of Iodine-131 therapy and issues related to its administration, degree of TSH suppression and the role of external beam radiotherapy in selected cases. The results of this study will help define treatment guidelines in Saskatchewan and improve patient care. It will also address the issues of efficient use of resources and patient convenience.

GRADUATE STUDENT POSTER AWARDS

Scott Dehm won third prize in the Alberta Cancer Board Annual Research meeting graduate student poster competition for the poster: "Transcriptional activation and alternative promoter usage of the human SRC gene in human colon cancer cell lines" by Scott Dehm and Keith Bonham.

At the 8th Annual Life Sciences Research Day at the University of Saskatchewan on January 19, 2001. The winners were as follows:

Ph.D category:
1st place - Shawn Ritchie (Dr. K. Bonham, supervisor) Characterization and regulation of the human SRC 1A promoter: The role of trans-acting factors in transcription, differentiation and transformation.
2nd place - Scott Dehm (Dr. K. Bonham, supervisor) Transcriptional activation and alternative promoter usage of the human SRC gene in human cancer cell lines.

M.Sc. category:
1st place and best poster overall - Stuart Scott (Dr. J. DeCoteau, supervisor) Frequency of methylated and unmethylated cyclin-dependent kinase inhibitor promoter alleles in human AML.
2nd place - Tim Chan (Dr. J. Xiang, supervisor) Engineering tumor cells with immunogenes.

Resident/Post-doctoral category:
2nd place - Anees Chagpar (Dr. J. DeCoteau, supervisor) Replication error positive phenotype: a potential prognostic marker in breast cancer.

EXTERNAL GRANTS (2000-2001)

The Role of A-Raf in Signaling Pathways - Dr. D. Anderson
Funding provided by MRC Regional Partnership Program

Protein:protein interactions in lysosomal targeting - Dr. D. Anderson
Funding provided by Natural Sciences and Engineering Research Council of Canada

Regulation of c-Src Expression in Human Cancer Cells - Dr. K. Bonham
Funding provided by CIHR/Regional Partnership Program

Transforming growth factor beta-1 resistance in human acute leukemia - Dr. J. DeCoteau, (Co-Investigators: A. Magliocco and D. Demetrick)
Funding provided by Medical Research Council of Canada

Genomic-Scale Gene Expression Profiling in Acute Myeloid Leukemia - Dr. J. DeCoteau, (Co-Investigator: D. Sheridan)
Funding provided by U of S College of Medicine Scientific Teaching and Research Fund

Abnormal DNA methylation in human diffuse large B-cell lymphomas - Dr. R. Lowsky (Co-Investigator: J. DeCoteau)
Funding provided by Health Services Utilization & Research Commission

Calmodulin-Regulated Proteins in Heart - Dr. R.K. Sharma
Funding provided by Heart and Stroke Foundation of Saskatchewan

N-myristoyltransferase: A Novel Molecular Target for Cancer - Dr. R.K. Sharma
Funding provided by Medical Research Council of Canada

Aliphatic propargylamines as antineosplastic modulators - Dr. R.C. Warrington
Funding provided by ALVIVA Biopharmaceuticals

Targeting cytokine to tumors by novel recombinant fusion proteins and adenovirus-mediated gene transfer - Dr. J. Xiang
Funding provided by Medical Research Council of Canada

Conformationally constrained recombinant peptides with the binding affinity for the tumor-specific NeuAca2-6GalNAcl-0-Ser - Dr. J. Xiang, (Co-Applicant: Dr. Z. Jia)
Funding provided by Natural Sciences and Engineering Research Council of Canada

Multi-user Equipment Grant - Dr. J. Xiang (Co-Applicants: Drs. D. Anderson, K. Bonham, J. DeCoteau and R.K. Sharma)
Funding provided by Medical Research Council of Canada

Research Projects

CLINICAL TRIALS (2000-2001)

Participation in Clinical Trials of the North Central Cancer Treatment Group (NCCTG), National Cancer Institute of Canada (NCIC) Clinical Trials, National Surgical Adjuvant Breast and Bowel Project (NSABP), and Drug Company Studies - M. Tirona, B. Walley and O. Keller

For the period April 1, 2000 to March 31, 2001, the Allan Blair Cancer Centre Protocol Office and the Saskatoon Cancer Centre Clinical Trials Office accrued a total of 145 patients in clinical trials. The Allan Blair Protocol Office was following 362 patients in 70 different studies and had 47 active clinical trials during that time period. The Saskatoon Cancer Centre was following 384 patients in 52 different studies and had 31 active clinical trials during that time period. In 2000-01, 83 cancer patients and five cancer control patients were accrued in the NCCTG clinical trials. Forty patients were accrued in NCIC clinical trials. Eight patients were accrued in NSABP study of Tamoxifen and Raloxifene (STAR) for the prevention of breast cancer. Three patients were entered in drug company cancer control studies and six patients were entered in drug company cancer treatment studies.

Participation in Children's Oncology Group (COG) - Regina - T. S. Goh

From April 1, 2000 to March 31, 2001, 22 patients were registered with COG. Eight patients were enrolled in therapeutic studies and 11 in non-therapeutic studies. Fourteen patients were not on therapeutic studies for various reasons and were given standard treatment. During this period, 8 new COG studies were approved. Sixty-seven protocols received annual re-approval and 35 addenda were also approved.

Participation in Children's Oncology Group (COG) - Saskatoon - K. Ali

Between April 1, 2000 and March 31, 2001, 22 new pediatric cases were seen at the Saskatoon Cancer Centre. Of these 22 new patients, two were enrolled in therapeutic studies, three were enrolled in both therapeutic and biology studies and the remaining 17 patients were registered with the Children's Oncology Group and given standard treatment. Two relapsed patients were enrolled in Phase I treatment studies and one of which was also enrolled on a non-treatment study. During this time period, six new studies were approved. Ninety-three protocols received annual reapprovals and 42 addenda's were also approved.

Participation in Radiation Therapy Oncology Group (RTOG) Clinical Trials - Saskatoon - I. MacLennan

During the reporting period from 1st April 2000 to 31st March 2001, nine clinical trials were active through the RTOG office and ten clinical trials were open for follow-up purposes. A total of three new patients were enrolled on clinical trials and forty-three patients were on follow-up after completion of active treatment. The active studies include seven phase III studies, one phase II study and one cancer control study. Considerable time is expended screening patients for possible participation; discussing clinical trials with patients and families; keeping physicians informed about clinical trials and fulfilling ongoing requirements for ethical review.

Affiliate Membership in Radiation Treatment Oncology Group (RTOG) and Enrolment of Patients in the Group's Clinical Research Protocols - Regina - C.T. Ago

Allan Blair Cancer Centre's application for affiliate membership in RTOG was accepted in the summer of 2000. Our full member institution is the Cross Cancer Institute. We will activate the membership as soon as the Institutional Review Board commences its activities.

Bonham, K., Ritchie, S.A., Dehm, S.M. Snyder, K. and Boyd, F.M. (2000). An Alternative, Human SRC Promoter and its Regulation by Hepatic Nuclear Factor-1a. J. Biol. Chem., 275, 37604-37611.

Cadman, P., and **Sidhu, N.P.S.** Feasibility of penumbra compensating filters for conformal prostate radiotherapy. Phys. Med. Biol. 45 (2000) 295-304.

Campbell, I., Magliocco, A., Moyana, T., Zheng, C., and **Xiang, J**. (2000). Adenovirus-mediated p16 gene transfer significantly suppress human breast cancer growth. Cancer Gene Therapy, 7, 1270-1278.

Campbell, I., Moyana, T., **Carlsen, S.**, and **Xiang, J**. (2000). Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth. Cancer Gene Therapy, 7, 37-44.

Dehm, S., Senger, M. and **Bonham, K**. (2001). SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Letters, 487, 361-371.

Dumonceaux, T. and **Carlsen S. A.** (2001). Isogloboside Biosynthesis in Metastatic R3230AC Cells Results from a Decreased GM3 Synthase Activity. Archives in Biochemistry and Biophysics, 389, 187-194.

Houshmand, S., Briggs, S., Campbell, C., McFadden, A., Al-Tweigeri, T. Prophylactic Mastectomy and Genectice Testing: An Update. Oncology Nursing Forum, November/December 2000.

Ichinohasama, R., Miura, I., Takahashi, N., Sugawara, T., Tamate, E., Endoh, K., Endoh, F., Naganuma, H., **DeCoteau, J.F.**, Griffin, J.D., Kadin, M.E., and Ooya, K. (2000). Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. Leukemia, 14, 169-82.

Ichinohasama, R., Miura, I., Takahashi, N., Sugawara, T., Tamate, E., Endoh, K., Endoh, F., Naganuma, H., **DeCoteau, J.F.**, Griffin, J.D., Kadin, M.E., and Ooya, K. (2000). Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. Leukemia, 14, 169-82.

Kakkar, R., Rajala, R.V.S., and **Sharma, R.K.** (2001). Biological function of cardiac high molecular weight calmodulin-binding protein. Pharm & Therap in the New Millennium (Gupta SK ed) Narosa Publishing House, 78-84.

Kakkar, R., Radhi, J.M., Rajala, R.V.S., and **Sharma, R.K.** (2000). Altered expression of high molecular weight calmodulin-binding protein in human cardiac ischemia. J Pathology 191, 208-216.

Kakkar, R., Wang, X., Radhi, J.M., Rajala, R.V.S., Wang, R., and **Sharma, R.K.** (2001). Decreased expression of high molecular weight calmodulin-binding protein and its correlation in the apoptosis in ischemia-reprefused rat heart. Cell Calcium 29, 59-71.

Kanthan, R., **Xiang, J.**, and Magliocco, A. (2000). P53, ERBB2 and TAG72 expression in the spectrum of ductal carcinoma in situ of the breast classification by the VAN NUYS system. Arch. Pathol. Lab Med., 124, 234-239.

King, T. R., Fang, Y., Mahon, E. S., and **Anderson, D. H.** (2000). Using a phage display library to identify basic residues in A-Raf required to mediate binding to the SH2 domains of the p85 subunit of phosphatidylinositol 3'-kinase. J. Biol. Chem., 275, 36450-36456.

Lowsky, R., Magliocco, A., Ichinohasama, R., Reitmair, A., Scott, S., Henry, M., Kadin, M.E., and **DeCoteau, J.F.** (2000). MSH2 Deficient Murine Lymphomas Harbor Acquired Frameshift Mutations in the Transforming Growth Factor Beta Receptor Type II Gene and Display Low not High Frequency Microsatellite Instability. Blood, 95, 1767-1772.

McDuffie, H. H., **Robson, D.L.** et al. An Exploration of the role of Family History of Cancer Among Four Rare Types of Cancer. American Journal Human Genetics, 2000; supplement 2, 67(4): 97.

Moyana, T., Kulaga, A., and **Xiang, J.** (2000). The spectrum of neuroendocrine differentiation amongst GI carcinoids. Comparison of histologic classification with Ki-67, P53 and bcl-2 immunostaining. Arch. Pathol. Lab Med., 124, 72-78.

Rajala, R.V.S., Dehm, S., Bi, X., **Bonham, K.** and **Sharma, R.K.** (2000). Expression of N-Myristoyltransferase inhibitor protein and its relationship to c-Src levels in human colon cancer cell lines. Biochim. Biophys. Res. Commun., 273, 1116-1120.

Publications

Raju, V.S. Rajala, Datla, R.S.S., and **Sharma, R.K.** (2001). Regulation of N-myristoyl-transferase in human colon cancer. Pharm & Therap in the New Millennium (Gupta SK ed) Narosa Publishing House, 246-253.

Rawson, N.S.B. and **Robson, D.L.** Concordance on the Recording of Cancer in the Saskatchewan Cancer Agency Registry, Hospital Charts and Death Registrations. Canadian Journal of Public Health, September-October 2000, Volume 91, NO. 5 pg. 390-393.

Semenciw, R.M., **Robson, D.L.** et al. Methodological issues in the development of the Canadian Cancer incidence atlas. Statistics in Medicine 2000, 19: 2437-2449.

Sharma, R.K. (2001). Differential activation and inhibition of calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes. Pharm & Therap in the New Millennium (Gupta SK ed) Narosa Publishing House, 254-271.

Sidhu, N.P.S., Rouvas, A., and **Cadman, P.** J. of App. Clinical Medical Phys. Vol 1, 4 (2000) 148-152.

Skarsgard. D., Groome P.A., Mackillop. W.J., Zhou, S., Rothwell, D., Dixon, P.F., O'Sullivan, B., Hall S., and Holowaty, E. Cancers of the upper aerodigestive tract in Ontario, Canada, and the United States. *Cancer2000*; 88: 1728-38.

Tai, P., Van Dyk, J., Yu, E., Battista, J., **Schmid, M.**, Stitt, L., **Tonita, J.**, Coad, T. Radiation Treatment for cervical esophagus - Pattern of Practice Study in Canada, 1996. Int J. Radiat Oncol Biol Phys 2000: 47: 703-12.

Tai, P., Hammond, A., Van Dyk, J., Stitt, L., **Tonita, J.**, Coad, T., Radwan, J. Pelvic fractures following irradiation of endometrial and vaginal cancers - a case series and review of literature. Radiat Oncol 2000; 56 (July): 23-8.

Tai, P.T.H., Yu, E., Winquist, E., Hammond, A., Stitt, L., **Tonita, J.**, Gilchrist, J. Chemotherapy in neuroendocrine / Merkel cell carcinoma of the skin (MCC) : case series and review of 204 cases. J Clin Oncol 2000; 18 (June): 2493-9.

Tai, P.T.H., Yu, E., **Tonita, J.**, Gilchrist, J. Merkel cell carcinoma (MCC) of the skin. J Cutan Med Surg 2000; 4: 186-95.

Tai, T.H.P. Merkel cell carcinoma of the skin. In: UpToDate, Rose BD (Ed), UpToDate, Wellesley, MA, 2000.

Xiang, J., Chen, Y., and Moyana, T. (2000). Combinational immunotherapy of established tumors with engineered tumor vaccine and adenovirus-mediated gene transfer. Cancer Gene Therapy, 7, 1023-1033.

Xiang, J. and Moyana, T. (2000). Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1. Interferon and Cytokine Res., 20, 349-354.

Xiang, J., Srivamadan, M., and Jia, Z. (2000). Study of B72.3 combining-sites by molecular modeling and site-directed mutagenesis. Protein Engng., 13, 339-344.

Bonham, K., Ritchie, S., Dehm, S. and Boyd. F.M. Human SRC Expression is Controlled by Two Closely Linked Alternative Promoters. Beyond the Genome: Understanding and exploiting molecules and cells in the third millennium. 18th International Congress of Biochemistry and Molecular Biology. Birmingham U.K. July 16-20, 2000.

Boyd, F. M., Ritchie, S. A., Dehm, S. M., and **Bonham, K**. An alternative SRC promoter is regulated by HNF-1, C/EBP and contributes to c-Src overexpression in human tumor cell lines. Annual Research Meeting, Alberta Cancer Board. Nov 19-21, 2000. Banff, AB.

Calvert, B. M., **Anderson, D.** and **Carlsen, S. A.** (2001) Identification and characterization of a novel putative metastasis suppressor (ms-1) gene differentially expressed in R3230AC rat mammary adenocarcinoma subpopulations. 8th Annual Life Sciences Research Day, Saskatoon January 19. 2001.

Calvert, B. M., **Anderson, D.** and **Carlsen, S. A.** (2000) Identification and characterization of a novel putative metastasis suppressor (ms-1) gene differentially expressed in R3230AC rat mammary adenocarcinoma subpopulations. Alberta Cancer Board Annual Research Meeting, Banff, AB, November 19-21, 2000.

Chagpar, A., Kerviche, A., Bergen, S., Senthilselvan, A., Magliocco, A., and **DeCoteau, J**. The frequent finding of loss of heterozygosity of hMLH1 is associated with the replication error phenotype in breast cancer. Proceedings of the 91st Annual American Association for Cancer Research Meeting, San Francisco, CA, April 2000.

Dehm, S. and **Bonham, K.**. Transcriptional Activation and Alternative Promoter Usage of the Human SRC Gene in Human Colon Cancer Cell Lines. The 8th Annual Life Sciences Student Research Day. University of Saskatchewan. Jan. 19, 2001. This poster won 2nd prize in the Ph.D. category.

Dehm, S. and **Bonham, K.** Transcriptional Activation and Alternative Promoter Usage of the Human SRC Gene in Human Colon Cancer Cell Lines. Annual Research Meeting, Alberta Cancer Board. Nov 19-21, 2000. Banff, AB. This poster won third prize in the poster competition.

Dehm, S. and **Bonham K**. A Reciprocal Relationship Between C-SRC Transcriptional Activation and Activating K-RAS Mutations in Human Colon Cancer Cell Lines. AACR 91st annual meeting, San Francisco April 1-5 2000.

Ector, L. and **Carlsen, S. A.** (2001) Human ms-1: a putative metastasis suppressor gene. 8th Annual Life Sciences Research Day, Saskatoon January 19. 2001.

Ector, L. and **Carlsen, S. A.** (2000) Human ms-1: a putative metastasis suppressor gene. Alberta Cancer Board Annual Research Meeting, Banff, AB, November 19-21, 2000.

Johnson, L.M., Mahon, E.S., and **Anderson, D.H.** Phosphorylation and Regulation of the Activity of A-Raf Substrates. Poster at the Eighth Annual Life Sciences Research Day. University of Saskatchewan. Saskatoon on January 19, 2001.

Mahon, E.S., Fang, Y., and **Anderson, D.H.** A-Raf and Receptor Tyrosine Kinase Interactions. Poster #2279 presented at the "American Association for Cancer Research" meeting in San Francisco between April 1-5, 2000.

Ritchie, S. and **Bonham, K.** Characterization and Regulation of the Human SRC1A Promoter: The Role of Transacting Factors in Transcription, Differentiation and Transformation. The 8th Annual Life Sciences Student Research Day. University of Saskatchewan. Jan. 19, 2001. This poster won 1st prize in the Ph.D. category.

Ritchie, S. and **Bonham, K.** Transcriptional regulation of the human C-SRC gene. AACR 91st annual meeting, San Francisco April 1-5 2000.

Ritchie, S., Boyd, M., Dehm, S., and **Bonham, K.** The SRC Pyrimidine Binding Protein, SPy, and its role in SRC Transcriptional Regulation. Annual Research Meeting, Alberta Cancer Board. Nov 19-21, 2000. Banff, AB.

Scott, S., Kimura, T., Ichinohasama, R., and **DeCoteau, J.F**. Frequency of methylated and unmethylated cyclin-dependent kinase inhibitor promoter alleles in human AML. Proceedings of the 92nd Annual American Association for Cancer Research Meeting, New Orleans, LA, March 2001.

Abstracts and Proceedings

Scott, S., Kimura, T., Ichinohasama, R., and **DeCoteau, J.F.** Methylation of CpG Sites within the p27KIP1 and p21WAF1 Promoters is not Associated with Loss of Detectable p27KIP1 and p21WAF1 mRNA in Human AML. Proceedings of the American Society of Hematology Annual Meeting, San Francisco, CA, December 2000.

Skarsgard, D. and **Tonita, J.** Adding prostate cancer tumour and treatment information to registry data: a feasibility study. Clin Invest Med 2000; 23 (4Suppl); S32 (abstract no. 196). Oral presentation at annual meeting of the Canadian Association of Radiation Oncologists, Edmonton, 2000.

Tai, T.H.P., Tonita, J., Dickof, P., Schmidt, M., **Schmid, M., Ago, T.,** Aryeetey, K., Ziarko, W.P., **Skarsgard, D., Liem, S.K., Smith, P.** Prophylactic cranial irradiation (PCI) revisited: Outcomes reserach. Scientific Program, Royal College of Physicians and Surgeons of Canada Annual Meeting, Clinical and investigative medicine, August 2000. Supplement to Vol 23, No. 4, ps30.

Tai, T.H.P. Salvage brachytherapy for nasopharyngeal carcinoma. Canadian Brachytherapy Group Meeting, 2000.

Tai, T.H.P. Brachytherapy for nasopharyngeal carcinoma. Proceedings for Nucletron User Group Meeting, Fuzhou, 25-27 September, 2000.

Tai, T.H.P., Yu, E., **Tonita, J., Dickof, P.,** Schmidt, M., **Schmid, M., Ago, T.,** Aryeetey, K., Ziarko, W.P., **Skarsgard, D., Liem, S.K., Smith, P.** Prophylactic crainial irradiation (PCI) revisited: Outcomes research. Proceedings of the American Society for Therapeutic Radiology and Oncology, 42nd annual meeting, 22-26 October, 2000. Int J Radiat Oncol Biol Phys, 48S:158.

Xiang, J. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. AACR meeting, San Francisco, CA, USA, April 1-4, 2000.

Xiang, J. Eradication of established tumors by combinational immunotherapy. AAI meeting, Seattle, Washington, USA, May 12-16, 2000.

Sylvia Fedoruk Prize in Medical Physics

Dr. Sylvia O. Fedoruk, a Medical Physicist with 35 years of dedicated and distinguished service to the Saskatchewan Cancer Program, retired in December 1986. On the occasion of Dr. Fedoruk's retirement, the Board of the Cancer Agency announced the establishment of the Sylvia Fedoruk Prize in Medical Physics in her honour and in recognition of her contributions to cancer control.

This annual award is presented to the author selected as having published the best paper in Medical Physics in the preceding year, and must relate to work carried out within a Canadian institution. An anonymous selection committee, appointed jointly by the Canadian College of Physicists in Medicine and the Canadian Organization of Medical Physics, reviews the entries and recommends the successful candidates.

The award has been presented to:

1987 *Robert Nishikawa, Gordon Mawdsley, Aaron Fenster, Martin Yaffe*, co-authors of the paper "Scanned-projection digital mammography", published in **Medical Physics**.

1988 *T.R. Mackie, A.F. Bielajew, D.W.O. Rogers, J.J. Battista*, co-authors of the paper "Generation of photon energy deposition kernels using the EGS Monte Carlo code", published in **Physics in Medicine and Biology**.

1989 *Duncan Galbraith*, author of the paper "Low-energy imaging and high-energy bremsstrahlung beams", published in **Medical Physics**.

1990 *Alex Bielajew*, author of the paper "On the technique of extrapolation to obtain wall correction factors for ion chambers irradiated by photon beams", published in **Medical Physics**.

1991 *Qing-San Xiang, R. Mark Henkelman*, co-authors of the paper "Motion artifact reduction with three-point ghost phase cancellation", published in **Journal of Magnetic Resonance Imaging**.

1992 *D.L.D. Mason, J.J. Battista, R.B. Barnett, A.T. Porter*, co-authors of the paper "Ytterbium-169: calculated physical properties of a new radiation source for brachytherapy", published in **Medical Physics**.

1993 *John M. Sabol, Ian C. Soutar, Donald B. Plewes*, co-authors of the paper "Mammographic scanning equalization radiography", published in **Medical Physics**.

1994 *R.M. Henkelman, G.J. Stanisz, J.K. Kim, M.J. Bronskill*, co-authors of the paper "Anistrophy of NMR properties of tissues", published in **Medical Physics**.

1995 *Wei Zhao, John Rowlands*, co-authors of the paper "X-ray using amorphous selenium: Feasibility of a flat panel self-scanned detector for digital radiology", published in **Medical Physics**.

1996 *Chris Henry, Terry Peters*, co-authors of the paper "Three-dimensional reconstruction of vascular trees. Theory and methodology", published in **Medical Physics**.

1997 *Corey Zankowski, Ervin Podgorsak*, co-authors of the paper "Calibration of photon and electron beams with an extrapolation chamber", published in **Medical Physics**.

1998 *Robin Kelly, Kevin Jordan, Jerry Battista*, co-authors of the paper "Optical CT Reconstruction of 3D Dose Distributions using the FBX Gel Dosimeter", published in **Medical Physics**.

1999 *Pratondo Busono, Esam Hussein*, co-authors of the paper "Algorithms for density and composition-discrimination imaging for fourth-generation CT systems", published in **Physics in Medicine and Biology**.

2000 *Martin Lachaine, B. Gino Fallone*, co-authors of the paper "Monte Carlo Simulations of X-ray induced Recombination in Amorphous Selenium", published in **Journal of Physics D: Applied Physics**.